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ABSTRACT
In this article, the 2010 European League against
Rheumatism (EULAR) recommendations for the
management of rheumatoid arthritis (RA) with synthetic
and biological disease-modifying antirheumatic drugs
(sDMARDs and bDMARDs, respectively) have been
updated. The 2013 update has been developed by an
international task force, which based its decisions mostly
on evidence from three systematic literature reviews (one
each on sDMARDs, including glucocorticoids, bDMARDs
and safety aspects of DMARD therapy); treatment
strategies were also covered by the searches. The
evidence presented was discussed and summarised by
the experts in the course of a consensus ﬁnding and
voting process. Levels of evidence and grades of
recommendations were derived and levels of agreement
(strengths of recommendations) were determined.
Fourteen recommendations were developed (instead of
15 in 2010). Some of the 2010 recommendations were
deleted, and others were amended or split. The
recommendations cover general aspects, such as
attainment of remission or low disease activity using a
treat-to-target approach, and the need for shared
decision-making between rheumatologists and patients.
The more speciﬁc items relate to starting DMARD
therapy using a conventional sDMARD (csDMARD)
strategy in combination with glucocorticoids, followed
by the addition of a bDMARD or another csDMARD
strategy (after stratiﬁcation by presence or absence of
adverse risk factors) if the treatment target is not
reached within 6 months (or improvement not seen at
3 months). Tumour necrosis factor inhibitors
(adalimumab, certolizumab pegol, etanercept,
golimumab, inﬂiximab, biosimilars), abatacept,
tocilizumab and, under certain circumstances, rituximab
are essentially considered to have similar efﬁcacy and
safety. If the ﬁrst bDMARD strategy fails, any other
bDMARD may be used. The recommendations also
address tofacitinib as a targeted sDMARD (tsDMARD),
which is recommended, where licensed, after use of at
least one bDMARD. Biosimilars are also addressed.
These recommendations are intended to inform
rheumatologists, patients, national rheumatology
societies and other stakeholders about EULAR’s most
recent consensus on the management of RA with
sDMARDs, glucocorticoids and bDMARDs. They are
based on evidence and expert opinion and intended to
improve outcome in patients with RA.
The management of rheumatoid arthritis (RA) rests
primarily on the use of disease-modifying antirheu-
matic drugs (DMARDs). These agents are com-
monly characterised by their capacity to reduce or
reverse signs and symptoms, disability, impairment
of quality of life, inability to work, and progression
of joint damage and thus to interfere with the entire
disease process.1 DMARDs form two major classes:
synthetic chemical compounds (sDMARDs) and
biological agents (bDMARDs). In this respect, a new
nomenclature for DMARDs was recently proposed
which we will adhere to in this report.2
Consequently, the term conventional sDMARDs
(csDMARDs) will be used to include chemical
agents such as methotrexate (MTX), sulfasalazine
and leﬂunomide, whereas tofacitinib, a new
sDMARD speciﬁcally designed to target janus
kinases ( JAKs), will be designated as a targeted
sDMARD (tsDMARD). The ﬁve available tumour
necrosis factor (TNF) inhibitors (adalimumab, cer-
tolizumab pegol, etanercept, golimumab and inﬂixi-
mab), the T cell costimulation inhibitor, abatacept,
the anti-B cell agent, rituximab, and the interleukin
(IL)-6 receptor (IL-6R)-blocking monoclonal anti-
body, tocilizumab, as well as the IL-1 inhibitor, ana-
kinra, will be subsumed as biological originator (bo)
DMARDs, while biosimilars (bs), such as bs-inﬂixi-
mab, recently approved by the European Medicines
Agency (EMA), will be named bsDMARDs.2
With abundant therapeutic options available and
insufﬁcient information on differential efﬁcacy and
safety, making treatment decisions in clinical prac-
tice remains challenging. To this end, the European
League Against Rheumatism (EULAR) has recently
developed recommendations for the management
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of RA with these drugs.3 These recommendations were based on
ﬁve systematic literature reviews (SLRs)4–8 and focused on indi-
cations for the use of, and suggestions for, differential and stra-
tegic employment of csDMARDs and bDMARDs based on
treatment targets, disease risk assessment, safety aspects and
contraindications. While some of the individual recommenda-
tions have elicited extensive discussions, all of them were based
on the evidence available at that point in time4–8 and on the
results of the discussions and votes by the expert committee.
Moreover, the EULAR recommendations have been used and
adopted widely, as suggested by their application as a template
for many national and regional recommendations after their
publication.9–12 However, as with most recommendations and
especially in a rapidly evolving ﬁeld such as RA, it was antici-
pated that the 2010 recommendations would need updating
within a few years.3 Indeed, more experience and additional evi-
dence on agents approved at that time, as well as data on new
compounds, have become available over the last 3–4 years,
motivating us to update the recommendations as described here.
METHODS
With the approval of the EULAR Executive Committee, the
convenor ( JSS) and epidemiologist (RL) who led the 2010
activity formed a Steering Group and a Task Force with the aim
of updating the 2010 EULAR recommendations for the manage-
ment of RA.
Task force
Comprised of 33 members from 11 European countries and the
USA, this EULAR Task Force included four patient representa-
tives, 24 rheumatologists, an infectious disease specialist, a
health economist and three fellows; care was taken to have a
good representation of clinicians and experts experienced in RA
clinical trials and their analysis from all European regions.
Initially, a Steering Group prioritised research questions and
search terms for the three SLRs. These searches expanded and
updated the available published information on efﬁcacy of
csDMARDs (as monotherapy or combination therapy, with and
without glucocorticoids), efﬁcacy of bDMARDs (as monother-
apy or combined with csDMARDs) and safety aspects of
csDMARDs and bDMARDs; treatment strategies were con-
tained in the present SLRs rather than being separate as in
2010.7 Although the SLRs informing the 2010 EULAR recom-
mendations also included a search on economic evaluations,8
the Steering Group felt that re-evaluation was not necessary
because the approval status and price of new agents such as
bsDMARDs was unknown.
Subsequently, with the help of their mentors, the three
fellows performed the respective SLRs using established data-
bases, including registry data for safety outcomes, and abstracts,
especially from recent meetings (American College of
Rheumatology 2012, EULAR 2012 and 2013). Details on and
results of the SLRs are reported separately.13–15 Levels of evi-
dence and grades of recommendation were determined accord-
ing to the standards of the Oxford Centre for Evidence-Based
Medicine.16
Consensus ﬁnding
At a subsequent meeting, these data were presented ﬁrst to the
Steering Group consisting of nine rheumatologists, an infectious
disease specialist and a patient representative, who drafted a pre-
liminary set of new recommendations based on their discus-
sions. The search results as well as the drafted proposal for the
recommendations were subsequently presented to the whole
Task Force and discussed in detail in four break-out groups
focusing on (i) csDMARDs and tsDMARDs, (ii) glucocorticoids,
(iii) bDMARDs and (iv) safety aspects. After these deliberations,
each subgroup reported their respective results and made new
proposals for the recommendations to the entire group. After
discussion, the Task Force then amended them as deemed
appropriate to achieve ﬁnal consensus, ultimately voting on each
individual recommendation. When an initial majority of 70% in
favour of—or against—a recommendation or formulation was
not achieved, the contents or wordings were amended until a
majority of the Task Force members approved the individual
item. The results of the ﬁnal ballot are presented for each of the
recommendations as a percentage of voting members. An ultim-
ate round of wording reﬁnements was carried out via electronic
communication but with no changes of the meaning permitted.
This was accompanied by anonymous voting on the strength of
recommendation (level of agreement) for each item on a 0–10
scale (0, no agreement at all; 10, full agreement).
A few principal considerations had already been developed by
the Steering Group before the SLRs and were subsequently
approved by the whole Task Force: (i) all of the 2010 recom-
mendations should be reconsidered on the basis of new available
supportive or contradicting evidence and voted upon; (ii) any of
the previous recommendations could be kept as had been for-
mulated, could undergo textual amendments, could be totally
abandoned or could be shifted from a prominent place in the
table listing the individual recommendations to the text accom-
panying them; (iii) although not yet approved and used in clin-
ical practice outside the USA at the start of the current activity,
it was deemed important to at least discuss and possibly formu-
late a recommendation on the application of tofacitinib based
on the evidence from the literature; (iv) while not yet approved
or used in practice in Europe or North America, it was also
deemed important to at least discuss and potentially express a
view on the place of biosimilars in the therapeutic arena based
on available evidence.
In line with these a priori considerations and the potential
need to provide some totally new recommendations, each of the
three overarching principles and 15 recommendations of the
consensus published in 2010 underwent thorough re-evaluation
for their validity based on information that had become avail-
able from trials and registries during the years since the last SLR
and consensus ﬁnding; where no new evidence had been found,
the evidence from the 2010 searches was applied.
RESULTS
General aspects
As with the 2010 recommendations, this 2013 update reﬂects
the balance of efﬁcacy and safety, but does not deal with the
toxicity of DMARDs in detail; this can be derived from the
results of the safety SLR; all three SLRs provide an important
adjunct to these recommendations, since they establish the evi-
dence base. Thus, in line with the 2010 recommendation, the
2013 update primarily considers agents with toxicity that
appears to be manageable, assuming that prescribers are either
aware of the respective risks or will adhere to the information
provided in the package inserts. However, where toxicity
appears to be a major issue, a general warning is included in the
respective recommendation.
Overarching principles
In line with the 2010 recommendations, the Task Force felt
again that some of the principles of treating RA are of such a
generic nature that they should be separated from individual
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recommendations on individual therapeutic approaches or com-
pounds. However, the sequence of these principles was changed
and the wording reﬁned (table 1).
A. Treatment of RA patients should aim at the best care and
must be based on a shared decision between the patient and
the rheumatologist. This principle was originally ranked as
B,3 but the Task Force decided that decision-sharing by
patient and rheumatologist is of such overwhelming import-
ance that it should spearhead the recommendations. Shared
decision-making includes the need to inform the patient of
the risks of RA and the beneﬁts of reaching the targeted
disease activity states as well as the pros and cons of respect-
ive therapies. It also means two-way communication and
joint or shared decision-making on the therapeutic target
and management plan as well as support for the patient to
develop personal preferences. The term ‘best care’ inher-
ently refers to the recommendations provided here.
B. Rheumatologists are the specialists who should primarily
care for RA patients. Shifting this item from rank A to B was
not at all meant to diminish the role of the rheumatologist
in the care of patients with RA. Indeed, the wording of this
principle remained unchanged and the rheumatologist is
already mentioned in item A and should constitute the main
counselling anchor for patients with RA. Further, the evi-
dence for provision of better care by rheumatologists in
comparison with other physicians (see item A: ‘best care’)
has been brieﬂy reviewed in the 2010 recommendations and
further corroborated since then.17 18 The term ‘primarily’
constitutes a short cut with several thoughts behind it that
go even beyond the considerations expressed in 2010: ﬁrst,
it reﬂects the necessity to involve other physicians experi-
enced in the care of RA patients, including experience in
novel therapies and their potential complications, where
there is a lack of trained rheumatologists; second, it is con-
sistent with multiprofessional care and thus with current
trends in some countries for an increasing role of non-
physician health professionals who are well trained in the
care of patients with RA, such as rheumatology nurses,19 as
long as the responsibility in general is in the hands of the
rheumatologist; and third, the term ‘primarily’ should also
remind the rheumatologist that multidisciplinary care may
sometimes be needed, especially when dealing with
comorbidities, such as cardiovascular disease,20 or complica-
tions of applied therapies, such as serious infections.
C. RA incurs high individual, societal and medical costs, all of
which should be considered in its management by the treat-
ing rheumatologist. Slightly reworded, the meaning of this
principle has not changed from last time. It consists of two
parts. The ﬁrst part relates to the costs incurred by RA for
the individual patient/family and society and mentions the
costs of modern therapies. It has been well established that
RA incurs a substantial socioeconomic burden,21 and this
has recently been supported by the Global Burden of
Disease studies.22 23 In this context, the cost-effectiveness of
treating RA has been repeatedly addressed, and the impact
of modern therapies on late, costly consequences of RA,
such as joint replacement surgery, is noteworthy.24 25 While
rheumatologists cannot generally be held responsible for
Table 1 2013 Update of the EULAR recommendations (the table of 2010 recommendations can be seen in the online supplement or the
original publication)
Overarching principles
A. Treatment of RA patients should aim at the best care and must be based on a shared decision between the patient and the rheumatologist
B. Rheumatologists are the specialists who should primarily care for RA patients
C. RA incurs high individual, societal and medical costs, all of which should be considered in its management by the treating rheumatologist
Recommendations
1. Therapy with DMARDs should be started as soon as the diagnosis of RA is made
2. Treatment should be aimed at reaching a target of remission or low disease activity in every patient
3. Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not
been reached by 6 months, therapy should be adjusted
4. MTX should be part of the first treatment strategy in patients with active RA
5. In cases of MTX contraindications (or early intolerance), sulfasalazine or leflunomide should be considered as part of the (first) treatment strategy
6. In DMARD-naïve patients, irrespective of the addition of glucocorticoids, csDMARD monotherapy or combination therapy of csDMARDs should be used
7. Low-dose glucocorticoids should be considered as part of the initial treatment strategy (in combination with one or more csDMARDs) for up to 6 months, but should
be tapered as rapidly as clinically feasible
8. If the treatment target is not achieved with the first DMARD strategy, in the absence of poor prognostic factors, change to another csDMARD strategy should be
considered; when poor prognostic factors are present, addition of a bDMARD should be considered
9. In patients responding insufficiently to MTX and/or other csDMARD strategies, with or without glucocorticoids, bDMARDs (TNF inhibitors*, abatacept or tocilizumab,
and, under certain circumstances, rituximab†) should be commenced with MTX
10. If a first bDMARD has failed, patients should be treated with another bDMARD; if a first TNF inhibitor therapy has failed, patients may receive another TNF inhibitor*
or a biological agent with another mode of action
11. Tofacitinib may be considered after biological treatment has failed
12. If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering‡ bDMARDs§, especially if this treatment is combined with a
csDMARD
13. In cases of sustained long-term remission, cautious reduction of the csDMARD dose could be considered, as a shared decision between patient and physician
14. When therapy needs to be adjusted, factors apart from disease activity, such as progression of structural damage, comorbidities and safety issues, should be taken into
account
*TNF inhibitors: adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars (as approved according to a thorough approval process, such as by EMA and/or FDA).
†The ‘certain circumstances’, which include history of lymphoma or a demyelinating disease, are detailed in the accompanying text.
‡Tapering is seen as either dose reduction or prolongation of intervals between applications.
§Most data are available for TNF inhibitors, but it is assumed that dose reduction or interval expansion is also pertinent to biological agents with another mode of action.
DMARD, disease-modifying antirheumatic drug; EMA, European Medical Agency; EULAR, European League against Rheumatism; FDA, Food and Drug Administration; MTX,
methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor.
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costs of treatment when attempting to provide best care in
line with overarching principle A, this item does reiterate
the responsibility of the rheumatologist to consider eco-
nomic implications when selecting between treatment strat-
egies or modalities with similar efﬁcacy and safety in the
short or intermediate term. Comparative meta-analyses and
head-to-head studies help us to judge similarities or differ-
ences between therapies,26–30 although—as will be discussed
below—the qualities of the studies may differ, which should
be thoroughly weighed in therapeutic decision-making. Cost
considerations by rheumatologists will become more import-
ant once biosimilar biological agents become available.31 In
parallel, payers (governments or social security agencies)
ought to take the overall individual and societal implications
of RA into account when making decisions on medical costs.
Recommendations
The discussion process of the Task Force led to 14 (rather than
the previous 15) recommendations. This reduction is due to the
elimination of three of the 2010 items (Nos 10, 11 and 14) and
the addition of two new recommendations. The decision to
delete old item 10 (mentioning the potential use of ‘azathiopr-
ine, cyclosporine A [or…cyclophosphamide]’) was taken unani-
mously; the decision to remove old item 11 (‘Intensive
medication strategies should be considered in every patient,
although patients with poor prognostic factors have more to
gain’) was likewise taken unanimously because those treatment
strategies are now well established, and several of the revised
recommendations inherently incorporate a strategic approach to
treating RA intensively. Finally, a 94% majority vote supported
deleting previous recommendation 14 (‘DMARD-naïve patients
with poor prognostic markers might be considered for combin-
ation therapy of MTX plus a biological’); for more details see
explanations on new No 9. However, it was simultaneously
decided to mention these therapeutic considerations in the text
accompanying pertinent recommendations.
The 14 recommendations arising from the current activity are
presented in table 1 and discussed in detail below. With the
exception of the ﬁrst two items, which are the mainstay of the
therapeutic approach to RA, they are not primarily weighted by
an order of importance, but rather follow a logical sequence
and procedural hierarchy. They are summarised in abbreviated
form in the algorithm presented in ﬁgure 1. Table 2 displays the
levels of evidence and grades of recommendation based on the
Oxford Levels of Evidence assessment, as well as the primary
voting results at the Task Force meeting and level of agreement/
strength of recommendation voting by the Task Force.
1. Therapy with DMARDs should be started as soon as the
diagnosis of RA is made. This recommendation is almost
the same as in 2010; the term ‘synthetic’ before DMARDs
was omitted to emphasise the generic nature of this recom-
mendation, focusing particularly on the importance of diag-
nosing RA early and treating it appropriately as soon as
such a diagnosis is presumed. To this end, the 2010
American College of Rheumatology (ACR)–EULAR classiﬁ-
cation criteria (which had only been in development when
the 2010 EULAR RA management recommendations were
discussed and are now well established)32 should be used to
support diagnosis and facilitate early introduction of effect-
ive therapy in RA. Although diagnosis relies on the individ-
ual rheumatologist’s judgement about the disease in a
particular patient at a particular point in time, whereas clas-
siﬁcation relates to the group level and is important
primarily for clinical studies, the new classiﬁcation estab-
lishes general criteria for early diagnosis. In the course of
its discussions, the Task Force reiterated both the import-
ance of the presence of clinical synovitis in at least one
joint (in line with the 2010 classiﬁcation criteria) and the
essential importance of starting DMARD therapy as soon
as possible.
2. Treatment should be aimed at reaching a target of remission
or low disease activity in every patient. The deﬁnition of
the treatment target was deemed of such fundamental
importance that the Task Force decided that aspects of
patient follow-up should not dilute it. Therefore the
former recommendation 2 is now split into two recommen-
dations, items 2 and 3. When the 2010 EULAR recommen-
dations were set forth to target remission,3 33 the ACR–
EULAR remission deﬁnition was still in development; in
the meantime, more stringent criteria have been pub-
lished34 by ACR and EULAR and should be applied in the
context of these recommendations for the actual deﬁnition
of remission as the optimal treatment target. Remission as
deﬁned by the Disease Activity Score based on 28 joint
counts (DAS28<2.6) is not regarded as sufﬁciently strin-
gent to deﬁne remission.34 The proportion of patients
reaching remission by the ACR–EULAR criteria in clinical
trials and practice is sufﬁciently large to warrant their pref-
erential and widespread use in daily care of RA patients.35–
38 A large array of data has conﬁrmed the value of reaching
stringent remission not only with regard to signs and symp-
toms of RA, but also with regard to achieving maximal
functional improvement and halting progression of struc-
tural damage39–44; thus good outcomes in terms of physical
function and structural changes are implicitly included in
targeting good clinical outcome. Moreover, the Task Force
agreed with the 2010 recommendations and similar recom-
mendations by another expert committee,27 namely that
low disease activity deﬁned by composite measures45 is a
good alternative goal for many patients who cannot attain
remission even today, especially those with long-standing
disease who actually constitute the majority of patients in
clinical care. Indeed, although somewhat worse than remis-
sion, low disease activity conveys much better functional
and structural outcomes than moderate or high disease
activity.38 40 46 Because a signiﬁcant proportion of patients
in clinical practice still do not attain a state of remis-
sion,37 47 48 implementation of this combined therapeutic
target appears to be particularly relevant and signiﬁcant.
Also, once any patient has reached a low disease activity
that is close to remission, the individual disease activity
variables have to be considered in detail before major thera-
peutic changes are made.
3. Monitoring should be frequent in active disease (every
1–3 months); if there is no improvement by at most
3 months after treatment start or the target has not been
reached by 6 months, therapy should be adjusted. In contrast
with the second half of prior recommendation 2, which also
dealt with follow-up and treatment adjustments that could
be interpreted or used differently than intended, statement 3
of the updated recommendations is very speciﬁc and clariﬁes
any potential incongruity. First, monitoring should be per-
formed as frequently as disease activity necessitates, namely
more frequently (such as every 1–3 months) with active
disease and less frequently (such as every 6–12 months)
once the treatment target has been stabilised. EULAR also
advocates the use of composite measures of disease activity,
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Figure 1 Algorithm based on the 2013 European League Against Rheumatism recommendations on rheumatoid arthritis management. ACPA,
anti-citrullinated protein antibody; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor; TNF, tumour necrosis factor.
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which include formal joint counts and the application of the
ACR–EULAR criteria for remission.34 45 Further, this item
clearly speciﬁes that the treatment target (remission or at
least low disease activity, see item 2) should be attained
within 6 months and not necessarily within 3 months; the
3-month time point relates solely to assessing improvement,
meaning reduction of disease activity from a high to at least
a moderate state by composite measures.45 If there is no
improvement in disease activity (such as persistence of high
disease activity as assessed by composite scores) after
3 months and provided that therapy has already been
adjusted to maximise treatment effect, the ongoing thera-
peutic regimen is usually unlikely to lead to the treatment
goal in many additional patients even by 1 year and should
be modiﬁed.49 Maximisation of treatment effects includes
reaching an optimal MTX dose within a few weeks and
maintaining the maximal dose (25–30 mg weekly) for at
least 8 weeks.50 If improvement is achieved at
3 months,51 52 it must be borne in mind that maximal efﬁ-
cacy will not be seen before 6 months in many patients with
most treatment strategies. This is true for all types of therap-
ies, including most biological agents. A similar approach
should be made if the treatment target (remission or low
disease activity) is not attained at 6 months. Of note, indi-
vidual patients may be well on their way to reaching the
targets of low disease activity or remission at 6 months and
might just take slightly more time to attain this desired state.
Therefore the change in disease activity from treatment start
to the 6-month time point will have to be taken into account
when making ﬁnal treatment decisions in the individual
patient.
4. MTX should be part of the ﬁrst treatment strategy in
patients with active RA. This statement (previously No 3)
remains unchanged. The Task Force felt reassured by the
respective SLR13 that MTX is a highly effective agent both
as monotherapy and in combination with glucocorticoids,
other csDMARDs and bDMARDs, and thus continues to
serve as an anchor drug in RA.53 As monotherapy with or
without glucocorticoids, it is effective in DMARD-naïve
patients and leads to low disease activity states or 70%
improvement rates according to the criteria of the ACR
(which correspond to nearly a state of low disease activ-
ity)54 in about 25–50% of patients with early RA within
6–12 months.35 55–60 Generally, this statement combines
three aspects: ﬁrst, by using the term ‘part of the ﬁrst treat-
ment strategy’, it implies that MTX, although effective as
monotherapy, may be combined with other agents, such as
glucocorticoids but also other csDMARDs (see above and
below); second, by stating ‘active disease’ (suggested deﬁni-
tions: Clinical Disease Activity Index (CDAI)>10,
DAS28>3.2 or Simpliﬁed Disease Activity Index (SDAI)
>11),45 it implies that some patients with low disease activ-
ity (deﬁned as CDAI≤10, DAS28<3.2, SDAI≤11) may not
need MTX and can do well on alternative csDMARD ther-
apies; the third aspect relates to patients previously treated
with other csDMARDs who should receive MTX at a sufﬁ-
cient dose and for sufﬁcient time before progressing to
potentially more intensive therapies. Important aspects
include dose optimisation,50 optimal use of folic acid,61
and recognition that the maximum effect of MTX is
attained only after 4–6 months55–59; in this respect, the
optimal dose (25–30 mg a week with folate substitution, or
somewhat less in the case of dose-limiting side effects62),
should be maintained for at least 8 weeks as an important
aspect on the way to ultimate treatment success.50 For
patients with contraindications to MTX, other drugs
should be used (see next recommendation).
5. In cases of MTX contraindications (or early intolerance),
leﬂunomide or sulfasalazine should be considered as part of
the (ﬁrst) treatment strategy. While MTX is usually quite
well tolerated, especially with folate supplementation,61 63
safety issues do exist62 64 and contraindications to MTX
include hepatic or renal disease; a further safety aspect of
concern may be MTX-induced lung disease. Sulfasalazine
and leﬂunomide were also included as alternatives for
MTX in 2010 in statement 4, so this item has only been
shifted. Both sulfasalazine and leﬂunomide have shown
clinical, functional and structural efﬁcacy,65–69 and,
although MTX doses in respective comparative trials may
not have been optimal, both have shown efﬁcacies similar
to MTX. No new studies have disproved this conclusion,
and both drugs have been used effectively in combination
with biological agents.70 71 Optimal therapeutic dosing of
sulfasalazine is 3–4 g/day as enteric coated tablets72–76; the
usual leﬂunomide dose is 20 mg/day. As with all other
agents mentioned, safety risks and contraindications should
be considered, and—aside from its higher cost—some
issues stated in relation to MTX above may also pertain to
leﬂunomide. Of note, sulfasalazine is considered to be safe
during pregnancy.77 Prior recommendation No 4 also men-
tioned injectable gold salts as an alternative to MTX. While
the Task Force does not at all withdraw its evidence-based
opinion on the efﬁcacy of parenteral gold salts (which is
similar to that of MTX in clinical, functional and structural
terms) set forth in 2010, gold salts are used rarely and,
indeed, are unavailable in many countries. Although some
members of the Task Force expressed safety concerns, these
Table 2 Levels of evidence (LoE), grades of recommendations
(GoR), strength of recommendation (SoR; = level of agreement),
and % of votes for the respective items as worded
LoE GoR SoR %
A. na na 9.8±0.9 100
B. na na 9.8±0.5 100
C. na na 9.6±0.6 100
1. 1a A 9.8±0.5 97
2. 1a A 9.6±0.7 100
3. 2b B 9.5±1.0 100
4. 1a A 9.6±0.9 100
5. 1a A 9.0±1.7 87
6. 1a A 9.5±0.8 100
7. 1a− A 8.9±1.2 73
8. 5 D 8.9±1.3 100
9. 1b A 9.2±1.2 90
10. 1a A 9.4±0.8 97
11. 1b*
5†
A*
D†
7.6±1.8 90
12. 2b B 8.7±1.8 100
13. 4 C 8.9±1.0 100
14 3b C 9.7±0.7 100
LoE and GoR are based on the recommendations of the Oxford Centre for
Evidence-Based Medicine.
*The general statement is evidence based.
†The place in the treatment algorithm is based on expert consensus opinion.
na, not applicable.
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were not found to be substantiated in the previous SLR4;
however, no study has evaluated intramuscular gold since
the last SLR was performed. Therefore it was decided to
remove gold salts from its relatively prominent place in the
table, while acknowledging that its efﬁcacy remains estab-
lished by high-quality evidence.78 Further, antimalarials,
such as hydroxychloroquine and chloroquine, are used in
RA, especially in combination therapy, but also as mono-
therapy in patients with very mild disease.79 Interestingly,
beyond their mild DMARD activity, antimalarials exhibit a
variety of positive metabolic effects and are also considered
to be safe during pregnancy.80 81 Because they may not retard
progression of joint damage to the same extent as other
agents,65 82 they have not been mentioned more prominently
in this statement, although patients with low disease activity
have a low propensity for joint destruction. Finally, compared
with the previous statement on these drugs, the term ‘early’
has now been added to ‘intolerance’ to indicate the Task
Force’s view that early intolerance to MTX (within 6 weeks)
should be viewed as a contraindication and not as a failure of
the ﬁrst treatment strategy. Of note, the Task Force decided
unanimously to delete recommendation 10, which also dealt
with potential alternative therapies for desperate cases (‘In
the case of refractory severe RA or contraindications to bio-
logical agents or the previously mentioned sDMARDs, the
following sDMARDs might be also considered, as monother-
apy or in combination with some of the above: azathioprine,
cyclosporine A [or exceptionally cyclophosphamide]’) from
the table of recommendations. Given the many currently
available effective csDMARDs and bDMARDs and the view
that the beneﬁt/risk ratio of the mentioned drugs was not con-
vincingly favourable, especially in relation to other therapies,
their use in a ﬁrst treatment strategy should be restricted to
rare, exceptional situations (for details see 2010
recommendations).3
6. In DMARD-naïve patients, irrespective of the addition of
glucocorticoids, csDMARD monotherapy or combination
therapy of csDMARDs should be used. In the previous set
of recommendations, item 5 read: ‘In DMARD-naïve
patients, irrespective of the addition of glucocorticoids,
sDMARD monotherapy rather than combination therapy
of sDMARDs may be applied.’ This wording expressed a
preference for monotherapy based on the respective
SLRs,64 83 which had revealed no superiority of combin-
ation therapy using csDMARDs when excluding the con-
comitant use of glucocorticoids. However, by saying ‘may’,
that statement did not generally oppose the use of
csDMARD combination therapy; this was also reﬂected in
the respective ﬁgure depicting the proposed algorithm.
Since then, several additional studies suggest that
csDMARD combination may be superior to MTX mono-
therapy, and some even found efﬁcacy to be similar to that
of bDMARDs.84–88 Nevertheless, although these trials
yielded similar results strengthening their interpretation,
controversy persists because of methodological limitations
of these studies,13 which were also clearly stated in some of
the reports themselves. Moreover, additional recent data
suggest that sequential monotherapy is as effective as com-
bination therapy in clinical, functional and structural out-
comes89 90 and that stepping up from MTX monotherapy
to a biological agent has signiﬁcant superiority over a com-
bination of csDMARDs.89 Nonetheless, the Task Force
agreed unanimously that the use of csDMARD combination
therapy should be mentioned as an appropriate alternative
strategy alongside the use of csDMARD monotherapy, with
or without glucocorticoids. The Committee thus felt that
both monotherapy and combination therapy of csDMARDs
are effective and that patient preferences and expectations
of adverse events should be considered when discussing
treatment options with them. In general, combination
therapy with csDMARDs should include MTX, since other
combinations have not been sufﬁciently studied. Finally, the
Task Force recognised the limitations of meta-analyses in
the light of new studies84 86 contradicting a meta-analysis
that had suggested similar structural efﬁcacy for csDMARD
combinations and bDMARD treatment.91
7. Low-dose glucocorticoids should be considered as part of
the initial treatment strategy (in combination with one or
more csDMARDs) for up to 6 months, but should be
tapered as rapidly as clinically feasible. As before, the Task
Force heavily debated the role of glucocorticoids (previ-
ously recommendation 6). Indeed, this item was reworded
(previously: ‘Glucocorticoids added at low to moderately
high doses to sDMARD monotherapy [or combinations of
sDMARDs] provide beneﬁt as initial short term treatment,
but should be tapered as rapidly as clinically feasible.’).
Rather than just making the general statement that gluco-
corticoids may ‘provide beneﬁt’, the Task Force now recom-
mends that they should be considered as part of the initial
therapeutic approach. This change is based on the respect-
ive SLR13 which includes additional information accrued
over the last few years.85 92 Low dose refers primarily to a
dose of 7.5 mg prednisone or equivalent per day or less.93
Mentioning glucocorticoids in a separate recommendation
results from their proven capacity to increase clinical, func-
tional and structural efﬁcacy when combined with
csDMARDs,92 94–96 and this combination has similar efﬁ-
cacy when compared with TNF inhibitors plus MTX60 97;
thus glucocorticoids, both in initially high and rapidly
tapered regimens (eg, COBRA) and at lower doses extended
over a year or two, may increase DMARD activity and are
even effective in this regard as monotherapy.98 99 However,
glucocorticoid monotherapy is not speciﬁcally recom-
mended by the Task Force and should only be used in
exceptional cases when all other DMARDs have contraindi-
cations. A separate EULAR committee has concluded that
the literature on safety of long-term glucocorticoid therapy
at low doses still has important gaps, but in general does
not support the notion of unacceptable safety issues100;
subsequently, that committee formulated management
guidelines that also address preventive measures against
glucocorticoid-induced adverse events.101 The current
SLRs13 15 are not in disagreement with any of the above
ﬁndings. Nevertheless, the adverse event proﬁle and
comorbidity implications of glucocorticoids (and thus their
beneﬁt/risk proﬁle) elicited a ﬁerce debate within the Task
Force. A compromise (based on expert opinion) to be more
speciﬁc with respect to the time frame of their application
by stating ‘up to 6 months’ rather than just ‘short term’
ultimately led to a majority vote; however, only 73% of the
members approved this item (the lowest majority level of
all recommendations), reﬂecting divergent opinions, with
both proponents of a stronger and a weaker recommenda-
tion voting against. However, the level of agreement
(strength of recommendation) was quite high (mean of 8.9)
upon ﬁnal anonymous grading. Thus, the Task Force sug-
gests using them only as bridging therapy and limiting their
use to a maximum of 6 months, ideally tapering them at
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earlier time points. However, neither chronic use of gluco-
corticoids in established RA nor intra-articular glucocortic-
oid applications were discussed. Of note, it was also
decided to change the algorithm in ﬁgure 1 from the 2010
version by downsizing the ‘−’ compared with the ‘+’ in the
‘±’ symbol to reﬂect the increasing agreement of the Task
Force that glucocorticoids should be combined with MTX
or other csDMARD regimens.
8. If the treatment target is not achieved with the ﬁrst
DMARD strategy, in the absence of poor prognostic factors,
change to another csDMARD strategy should be considered;
when poor prognostic factors are present, addition of a
bDMARD should be considered. Slightly reworded com-
pared with 2010, this statement reiterates the unanimous
view of the Task Force that risk stratiﬁcation is an import-
ant aspect in the therapeutic approach to RA. These risks
have been well deﬁned over the years and include a high
disease activity state, autoantibody positivity (rheumatoid
factor and/or antibodies to citrullinated proteins) and the
early presence of joint damage.102 103 In patients with a
low risk of poor RA outcome, another csDMARD strategy
(plus glucocorticoids) would be preferred, while in patients
with a high risk, the addition of a bDMARD would be pre-
ferred. It should be noted that the Task Force changed the
sequence compared with the 2010 recommendation, since
it assumed that many patients may not be at high risk after
a ﬁrst DMARD strategy, especially in terms of a reduced
disease activity and maybe even lower autoantibody levels,
and that a rapid change of the csDMARD regimen within
6 months, in line with recommendation 3, may convey
further efﬁcacy for a signiﬁcant proportion of patients.
‘Change’ rather than the previously used ‘switch’ is seman-
tically more in line with potentially adding drugs, especially
in patients initially treated with MTX monotherapy, and
inherently also comprises switching. ‘Another conventional
DMARD strategy’ has to be seen in relation to the ﬁrst
DMARD strategy; if the ﬁrst DMARD was MTX mono-
therapy, then a switch to, or the addition of, other
csDMARDs would be the appropriate choice; if the ﬁrst
DMARD strategy was combination therapy of MTX, sulfa-
salazine and hydroxychloroquine, then the next csDMARD
strategy to choose in patients at low risk of poor outcome
may be leﬂunomide, all of this under the proviso that
optimal doses of the csDMARDs have already been used
before (see above). The term ‘considered’ was used in both
instances to reﬂect the Committee’s preferences, but inher-
ently acknowledges and implies that treatment decisions
have to be made individually and that using a bDMARD
after a ﬁrst csDMARD also in a patient with lower risk of a
poor outcome may be appropriate, just as using another
csDMARD strategy in a patient at high risk of a poor
outcome may be appropriate, as long as the target-oriented
strategy to attain remission or low disease activity within
6 months remains paramount; the latter approach, indeed,
may be a common or enforced approach in many health-
care systems. Studies suggesting that step-up csDMARD
combination therapy was as effective as a step-up combin-
ation of a biological agent with MTX87 88 104 were seen to
be in conﬂict with results from other studies showing better
efﬁcacy of addition of a bDMARD.89 Obviously, and for
reasons of clarity, when speaking of csDMARDs, the Task
Force had only the hitherto employed csDMARDs in mind
and not any potential new targeted synthetic (ts) DMARD,
such as a kinase inhibitor.
9. In patients responding insufﬁciently to MTX and/or other
csDMARD strategies, with or without glucocorticoids,
bDMARDs (TNF inhibitors, abatacept or tocilizumab, and,
under certain circumstances, rituximab) should be com-
menced with MTX. This point was approved as worded by
90% of the participants. First, the Task Force reiterated
here that bDMARDs should primarily be started when
patients did not achieve the therapeutic target after treat-
ment with csDMARDs for 6 months (or had no improve-
ment at 3 months). Second, it explicitly deﬁned the agents
it meant when mentioning ‘biological DMARDs’. In the
2010 recommendations, the Committee had added ‘current
practice would be to start a TNF inhibitor’, and explained
this expert opinion with the long-term use of TNF blockers
and the availability of registry data when compared with
abatacept and tocilizumab; this was simply an expression of
a preference based on their larger and longer evidence base
and was not intended to preclude use of other biological
agents after csDMARD failures. Also, at that time, their
application in patients with an inadequate response to
csDMARDs was not yet approved for tocilizumab in the
USA and for abatacept in Europe. Meanwhile, the approval
status has changed for both drugs, the clinical experience
with these agents has now grown for several years, and
initial registry data do not seem to reveal differences in
their safety proﬁles from the clinical trial data or when
compared with TNF inhibitors.105–109 Moreover, a direct
comparison of abatacept and adalimumab in patients with
active disease despite MTX revealed very similar efﬁcacy
and overall safety.110 Therefore the Task Force decided by a
90% majority vote that no preference of one over another
biological agent should be expressed in the 2013 update of
the recommendations. However, the Task Force recognised
that there was still more experience with TNF inhibitors
than with other bDMARDs, and that more safety data from
registries would be desirable for the newer bDMARDs.
Notably, IL-1 inhibitors have not shown strong efﬁcacy
when compared with other bDMARDs in meta-analyses, so
anakinra is not speciﬁcally mentioned in the abbreviated
recommendation; nevertheless, some patients may respond
to this bDMARD. Thirdly, the Task Force intentionally
added ‘under certain circumstances rituximab’; while ritux-
imab is approved for use after patients have responded
insufﬁciently to TNF blockers, the Committee acknowl-
edged that trial data in patients who were naïve for
csDMARDs and those who had an inadequate response to
csDMARDs have been published111 112 (level 1 evidence)
and that, in the presence of certain contraindications for
other agents—such as a recent history of lymphoma, latent
tuberculosis (TB) with contraindications to the use of
chemoprophylaxis, living in a TB-endemic region, or a pre-
vious history of demyelinating disease—rituximab may be
considered as a ﬁrst-line biological agent. Some rheumatol-
ogists also prioritise this drug in patients with a recent
history of any malignancy, because there are no indications
that rituximab use is associated with the occurrence of
cancers113 114; furthermore, rituximab is the least expensive
biological agent at present. Fourth, when speaking of TNF
inhibitors, the Task Force listed the presently approved
agents, adalimumab, certolizumab pegol, etanercept, goli-
mumab and inﬂiximab, but also decided to mention biosi-
milars under the proviso that they become approved in the
USA and/or Europe; current data suggest that at least one
biosimilar, CT-P13, has a similar efﬁcacy and safety proﬁle
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to the original antibody, inﬂiximab, in RA and axial spon-
dyloarthritis.115 116 Fifth, the Task Force felt that all
bDMARDs should be used preferentially in combination
with MTX or other csDMARDs. For neither TNF inhibi-
tors nor rituximab or abatacept has monotherapy been con-
sistently found to be superior to MTX alone, whereas
combination therapy has; a dose of 10 mg MTX or more a
week appears to be effective and appropriate for use with
adalimumab and inﬂiximab63 117 and, until proven other-
wise, also with all other TNF inhibitors. Only tocilizumab
has been repeatedly demonstrated to be superior as a
monotherapy over MTX or other csDMARDs, although
the Japanese study had an oplen label design and the MTX
dose was low.118 119 In 2010, the Committee explicitly
mentioned that a three-arm trial in early RA is needed to
gain full insight, and, most recently, these data became
available, albeit only in abstract form,120 revealing that only
in combination with MTX tocilizumab (8 mg/kg) showed
consistent signiﬁcant superiority over MTX with regard to
clinical, functional and structural outcomes. The other
arms, tocilizumab monotherapy (8 mg/kg) and tocilizumab
(4 mg/kg) in combination with MTX, showed superiority
mainly in reaching the primary clinical end point (DAS28–
erythrocyte sedimentation rate <2.6, a measure con-
founded by placing a high weight on acute phase reactant
levels121), with only numeric differences in most of the
clinical and functional secondary end points, most of which
did not reach statistical signiﬁcance. On the other hand, a
head-to-head trial in patients with established RA who
stopped MTX therapy revealed tocilizumab monotherapy
to be superior to adalimumab monotherapy in most
(though not all) endpoints.36 Thus, if biological monother-
apy must be initiated, tocilizumab has some supportive evi-
dence, but taken together, the data strongly support the use
of all biological agents in combination with MTX. While
clinical response is usually maintained even on withdrawal
of MTX in patients receiving established therapy with
MTX plus tocilizumab or a TNF inhibitor (and therefore
presumably also other bDMARDs),122–124 there is rarely a
reason to withdraw MTX, since, with established therapy,
it is usually well tolerated. Also monotherapy is not a major
recommendation by the Task Force, which clearly preferred
maintenance of combination therapy. Finally, it is important
to note that the Task Force agreed to abandon former rec-
ommendation No 14: ‘DMARD-naïve patients with poor
prognostic markers might be considered for combination
therapy of MTX plus a biological’. In 2010 it was already
stated that early use of a biological agent should only be
considered in exceptional patients; however, as it stood,
this statement could have been misinterpreted as advocating
use of biological agents even before an initial csDMARD
strategy had failed. With the current decision, the use of
bDMARDs before trying a csDMARD approach is even
more strongly discouraged than signiﬁed by the 2010 rec-
ommendation. The majority of the current Committee
members felt that using a treat-to-target strategy that gave
patients the initial opportunity to respond to treatment in
line with items 4, 5 and 7 still provides the option of
adding a biological agent within 6 months—and thus quite
early in the disease course or therapeutic chronology—if
the treatment target was not reached. This approach was
supported by several recent clinical trials.29 88 125 126
Although bDMARDs in comparison with csDMARDs in
early disease confer a signiﬁcant structural beneﬁt, this
beneﬁt was deemed to be neither sufﬁciently large nor suf-
ﬁciently frequent, provided that a treat-to-target strategy
with treatment adaptations within 6 months was adhered
to.125–127 This decision was probably the most heavily
debated one: an initial ballot revealed a 94% majority for
deleting the old recommendation No 14; subsequently,
after thorough discussions, a re-voting process was soli-
cited, but only 33% of the members voted for re-inclusion
of old recommendation No 14. In this context it should be
clariﬁed that the Task Force was fully aware of the data in
patients with early RA who have signiﬁcantly higher
response rates with bDMARDs combined with MTX than
MTX alone; however, embedded within this responder
population are good responders to MTX monotherapy
who experience about 25% (or more) ACR70 improvement
(corresponding to a low disease activity state including
remission) across studies without any additional treatment
adaptations being allowed over a 1-year trial period; in clin-
ical practice, many of these patients would have been over-
treated if they had received biological agents instead,
placing them at a potentially increased risk of serious
adverse events and incurring high costs. Also, it must be
borne in mind that the BeSt study showed that csDMARDs
plus glucocorticoids led to very similar initial clinical, func-
tional and structural results as with bDMARDs,97 and the
IMPROVED trial showed a very high rate of good out-
comes using MTX plus low-dose glucocorticoids within a
few months.60 Nevertheless, there may still be an excep-
tional patient in whom the use of a bDMARD in combin-
ation with MTX as the ﬁrst DMARD strategy is considered
appropriate. One can imagine patients whose professional
or family life entirely depends on a rapid complete reso-
lution of the joint symptoms and where glucocorticoids as
adjunctive therapy with csDMARDs have failed or cannot
be used because of contraindications. In such cases, the
exceptional use of a biological agent is not precluded now
that we have dismissed this recommendation from its
former place in the table, but the prominence that could be
misinterpreted has now been removed. Importantly,
however, there are studies suggesting that early induction
therapy with anti-TNF plus MTX may result in good out-
comes even after withdrawal of the biological agent.128 129
Nevertheless, another study, although partly conﬁrming
these results, resulted in a relatively high relapse rate on
withdrawal of the TNF inhibitor.130 Thus, more data are
needed to support induction therapy, but further evidence
conﬁrming the maintenance of remission after withdrawal
of the biological agent may lead to a paradigm change in
our approach to treating RA (see item 12).
10. If a ﬁrst bDMARD has failed, patients should be treated
with another bDMARD; if a ﬁrst TNF inhibitor therapy has
failed, patients may receive another TNF inhibitor or a bio-
logical agent with another mode of action. A consequence
of item 9, recommendation 10 simply states that once the
treatment target has not been reached with an initial bio-
logical therapy, other bDMARDs should be used; no pref-
erence is stated. The second part of this recommendation
focusing on patients who have initially received a TNF
inhibitor may seem somewhat redundant. However, it has
two purposes: (i) to express the conclusion of the Task
Force that current evidence does not suggest any one agent
to be better than another TNF inhibitor when active
disease prevails despite initial treatment with a TNF
blocker; (ii) over the next few years, new biological agents
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targeting the IL-6 receptor (sarilumab) or IL-6 (clazakizu-
mab, sirukumab) may become available131–133; without
speciﬁc note on the options after failure of an initial TNF
inhibitor therapy, one could infer that potentially approved
new IL-6 inhibitors might be used after failure of tocilizu-
mab, but in contrast with TNF inhibition, the efﬁcacy of
such an approach is currently unknown for IL-6 inhibition
(or costimulation blockers or rituximab). Of note, with bio-
similars approaching, it is self-evident that an inﬂiximab
biosimilar cannot be regarded as ‘another TNF inhibitor’ in
patients with an insufﬁcient response to inﬂiximab. This
recommendation was voted for by 97% of the members.
11. Tofacitinib may be considered after biological treatment has
failed. Tofacitinib, a JAK inhibitor, was approved for the
treatment of RA in the USA, Japan and Russia at the time
of the Task Force’s meeting on 9 April 2013. For reasons
stated above, an a priori decision had been made to address
tofacitinib in the recommendations based on evidence of
efﬁcacy and safety available from the literature and accrued
in the course of the respective SLR.13 Tofacitinib is not a
bDMARD, but a synthetic chemical compound. It is a tar-
geted molecule interfering with speciﬁc signal-transduction
pathways and thus could not be subsumed within the term
‘conventional synthetic DMARDs’. Therefore the Task
Force decided to address its use in a separate recommenda-
tion as a tsDMARD, rather than as part of csDMARDs or
bDMARDs.2 The evidence from published papers and
abstracts has convinced the Committee that tofacitinib is
sufﬁciently efﬁcacious in improving clinical, functional and
structural outcomes to be considered a DMARD.134–136
The fact that the 5 mg dose approved in the USA and
Japan just misses statistical signiﬁcance for inhibition of
joint damage progression compared with placebo at
12 months (p=0.06)137 did not preclude the Task Force
from recognising its structural efﬁcacy, given signiﬁcant
radiological differences at this dose in another trial.138
However, little is currently known about its long-term
safety. Data from clinical trials reveal a numerical increase
in serious infection rates compared with controls; herpes
zoster infections in particular appear to be more common
than seen with TNF inhibitors;134 139 several cases of TB
and non-TB opportunistic infections have been reported;
lymphocytopenia and anaemia also occur, and haemoglo-
bin levels appear to increase less upon clinical improvement
than seen with csDMARDs and bDMARDs. In light of the
many available csDMARDs and bDMARDs that have long-
standing clinical experience data, the Task Force felt that
tofacitinib should primarily be used when bDMARDs have
been insufﬁciently effective, even though it is already
approved in the USA, Japan, Russia and meanwhile
Switzerland for use after failure of csDMARDs. Indeed, the
discussion initially focused on whether tofacitinib should
only be recommended for use only after failure with two
bDMARDs with different modes of action, but ultimately it
was decided to just reﬂect this discussion item in the
accompanying text and not in the recommendation. More
clinical experience and safety data from registries, with a
particular focus on serious infections, herpes zoster and
malignancies, will be needed before the actual place of tofa-
citinib in the treatment sequence can be clariﬁed, and at
present the Committee did not feel that tofacitinib was
safer or more efﬁcacious than rituximab, which, according
to currently existing labelling, should be used after TNF
inhibitor failure. While the Task Force mainly focused on
efﬁcacy and safety, it also considered economic aspects, as
supported by GRADE140 and as occurred in the 2010
recommendations when all recommendations were sup-
ported by cost-effectiveness data, with the exception of
starting biological agents before sDMARDs.8 Given con-
strained healthcare budgets, the inefﬁcient use of healthcare
resources (ie, funding those interventions that are not cost-
effective) often results in either a lost opportunity to
improve the health of other individuals with cost-effective
interventions or increased costs through taxes or insurance
premiums. Hence the Committee noticed that the annual
cost of tofacitinib in the USA and Switzerland is currently
about US$25 000 and CHF25 000, respectively, placing it
at a similar level to biological agents.141 142 Notably, the
ﬁrst biosimilar has been approved in Europe in the mean-
time143 144 and is expected to be priced at lower levels
than the currently available bDMARDs.31 Therefore,
although the Task Force appreciates that tofacitinib is an
oral ﬁrst-in-class drug with a different mechanism of action
and is aware of the approval situation in the USA, Japan
and other countries, it did not believe it was yet possible to
conclude that tofacitinib has a similar safety proﬁle to toci-
lizumab or other biological agents for which far more
person-years of exposure have been accumulated and
reported to date. Thus, additional long-term safety data
and clinical experience will be needed to determine an
overall beneﬁt/harm ratio. Also, a proper cost-effectiveness
analysis would be desirable. Accordingly, the Committee
preferred not to recommend tofacitinib after MTX failure
as it did for other biological agents. Among the Task Force
members, 90% voted in favour of this recommendation as
phrased here. Of particular importance, at the time of the
Task Force’s meeting on 9 April 2013, it was unknown
when the EMA would release its decision on the approval
of tofacitinib. Thus, the discussions, formulation of recom-
mendation, explanatory stipulations and on-site voting of
the Committee occurred before EMA published its ﬁrst and
second negative decision on tofacitinib (with resubmission
being planned by the company).145–147 Anonymous voting
on the level of agreement (strength of recommendation),
however, occurred electronically after the ﬁrst EMA deci-
sion became known and was the lowest of all items (7.6 on
a scale of 0–10), which may have been inﬂuenced by this
information.
12. If a patient is in persistent remission after having tapered
glucocorticoids, one can consider tapering bDMARDs, espe-
cially if this treatment is combined with a csDMARD. In
contrast with 2010—when a similar recommendation was
stated—more evidence is now available and there was
unanimous approval within the Task Force. In established
RA, the available data suggest that most patients ﬂare upon
withdrawal of a TNF inhibitor,148–151 and more profound
and persistent responses increase the likelihood of mainten-
ance of a good outcome with csDMARDs even after with-
drawal of the bDMARD.150 In the PRESERVE trial, the
time frame was at least 4 months.152 However, for early
RA, the data are somewhat contradictory. While the
primary target in early RA clearly should be stringent
remission,33 34 most data on withdrawal of bDMARDs
come from patients who are in sustained low disease activ-
ity. The OPTIMA trial showed that a 6-month induction
regimen with adalimumab plus MTX soon after diagnosis
may be sufﬁcient to allow most patients to maintain low
disease activity or remission after open label and even after
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double-blind withdrawal of the TNF inhibitor128 153 154;
however, while similar ﬁndings on withdrawal of a TNF
blocker were obtained in an open label fashion in the HIT
HARD study,129 somewhat contradicting data were seen in
the PRIZE trial, where dose reduction but not withdrawal
of the biological agent was accompanied by maintenance of
good outcome.130 Thus, only if further and more broadly
conﬁrmed can short-term inclusion of a biological agent in
a ﬁrst DMARD strategy become a true option (see discus-
sion to recommendation No 9). On the other hand, reduc-
tion of the TNF inhibitor dose after attainment of
DAS28<2.6 in early RA allows excellent outcomes to be
maintained,130 as also seen in established RA.152 155 While
most studies on dose reduction or withdrawal have been
performed with TNF blockers, some data on other
bDMARDs are emerging with similar overall results,156–158
but clearly more information is needed in this regard.
Importantly, before bDMARDs are tapered, glucocorticoids
should have been withdrawn in line with point 7. Also of
note, reinstitution of bDMARDs appears to allow the good
outcome to be recaptured.150 156 159
13. In cases of sustained long-term remission, cautious reduc-
tion of the csDMARD dose could be considered, as a shared
decision between patient and physician. Except for minimal
rewording (the term ‘titration’ is replaced by ‘reduction’),
this item is identical with point 13 of the 2010 recommen-
dations; it refers solely to those patients in whom glucocor-
ticoids, if used, have already been stopped and/or who have
attained and maintained the targeted therapeutic state on
csDMARDs or those in whom bDMARDs have been suc-
cessfully withdrawn (see above). This recommendation
received 100% of the votes. As stated then, it must be
borne in mind that stopping csDMARDs in patients with
established RA in remission is followed by ﬂares in about
70% of patients, twice as frequently as maintaining therapy
irrespective of regimen.160 161 Therefore the focus of this
item is on csDMARD reduction rather than cessation. On
the other hand, drug-free remission may be an option in
patients in whom therapy was initiated very early and who
therefore also had achieved remission early in their disease
course.162 Of note, in light of the availability of the ACR–
EULAR remission deﬁnitions, the term ‘persistent remis-
sion’ in this recommendation primarily pertains to these
deﬁnitions; however, formal DMARD withdrawal studies
using them have not yet been performed.
14. When therapy needs to be adjuusted, factors apart from
disease activity, such as progression of structural damage,
comorbidities and safety issues, should be taken into
account. Again, this point is essentially identical with the
last recommendation of 2010 and was unanimously
approved at the Task Force meeting. It is intended to raise
awareness that reaching the outcome of low disease activity
or remission is not an absolute prerequisite and that it is
equally important to account for comorbidities and other
contraindications when targeting a good outcome.
Conversely, high disease activity is typically associated with
comorbidities,163 164 so effective therapeutic intervention
may also prevent comorbidity.165–167 Finally, some patients
with low disease activity may still develop seriously pro-
gressive radiographic joint damage, so after potential lag
periods have been accounted for to recognise progres-
sion,168 such patients may then need intensiﬁcation of
therapy.
DISCUSSION
The 2013 update of the EULAR RA management recommenda-
tions comprises three overarching principles and 14 recommen-
dations. The overarching principles bring the patient into even
closer focus than in 2010 by moving shared decision-making to
become principle A.
In recommendation 2 the Task Force reconﬁrmed that the thera-
peutic target was low disease activity (especially in patients with
established RA) or remission (especially in patients with early,
newly diagnosed RA), although the target may have to be modiﬁed
in accordance with comorbidities and safety considerations (item
14); importantly, since publication of the 2010 recommendations,
ACR and EULAR have provided a new index- and Boolean-based
deﬁnition of remission, for both clinical trials and practice, and
these criteria should be used accordingly.34
Compared with the 2010 recommendations, the current update
continues to advocate the efﬁcacy of csDMARDs as monotherapy
or combination therapy as the initial DMARD treatment strategy,
ideally combined with glucocorticoids, which—as now proposed—
should primarily be of low dose (≤10 mg per day) and applied for
only a limited time (6 months; item 7). Intra-articular application of
glucocorticoids was not part of the search activities, but is evidently
an important aspect in the treatment of RA, especially when there is
residual joint activity in patients who do well on DMARD therapy
otherwise.169 170
The Task Force now also regards all currently approved
bDMARDs as being similarly effective (with the exception of
anakinra) and generally safe for use as an initial biological
therapy after csDMARD failure. While the 2010 Task Force had
recognised a shortage of longer-term and, especially, registry
data on non-TNF inhibitor biological agents, these have now
become available to a sufﬁcient extent to warrant this change.
However, there is still a need for more observational/registry
data for abatacept, rituximab and tocilizumab; there are still
many fewer ‘real world’ safety data available for these three
compounds than for the TNF inhibitors.
Further, in the 2013 update, the preference to use a
bDMARD in combination with csDMARDs, particularly MTX,
rather than as monotherapy is reiterated. Moreover, although
the 2010 Task Force made clear statements disfavouring bio-
logical therapy as part of the initial DMARD strategy, the 2013
Task Force wished to enforce this point and avoid any misunder-
standing by abandoning any statement in this respect within the
abbreviated recommendation statements. The Task Force had
sufﬁcient evidence and was in full agreement that disease-
modifying therapy should start with csDMARDs, ideally com-
bined with glucocorticoids, and that, in a treat-to-target
approach, patients who do not attain the therapeutic target by
6 months and have poor prognostic markers would beneﬁt to a
similar extent from the addition of biological agents as if they
had received them from the beginning. This approach prevents
overtreatment of a signiﬁcant proportion of patients who can
achieve low disease activity or remission with an initial
csDMARD plus glucocorticoid strategy. There was also agree-
ment that the current lack of support for initiating the thera-
peutic cascade with bDMARDs might fade if the promise of
persistent good outcomes following withdrawal of biological
agents after a respective induction therapy in early RA is
maintained.129 154
The Task Force now also brieﬂy addressed the use of
bsDMARDs. Currently, data are available for one biosimilar
inﬂiximab poduct115 which shows similar efﬁcacy and safety
proﬁles to the original biological agent and was placed alongside
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the other TNF inhibitors in the therapeutic cascade; it is
assumed that the price of this biosimilar will be signiﬁcantly
lower. Finally, the Task Force also dealt with the available data
for tofacitinib.13 The abundance of efﬁcacy data available has
convinced the Task Force that tofacitinib at the twice daily 5 mg
dose has clinical, functional and structural efﬁcacy resembling
that seen with bDMARDs; this may not be surprising given its
pharmacological proﬁle, namely inhibition of the JAK pathway,
which is involved, among others, in IL-6 signalling. However, as
detailed in the Results section, some safety aspects of tofacitinib
are of concern and precluded recommendation of its use before
the failure of at least one and preferably two biological agents,
since many bDMARDs are currently available on the market
and familiar to rheumatologists. In the absence of a cost-
effectiveness analysis, the Task Force was also concerned about
the remarkably high price in the USA (and meanwhile also in
Switzerland).141 142 While the Task Force’s major focus was and
should be efﬁcacy and safety of available therapies, it did not
ignore its own overarching principle C, which includes cost con-
siderations of medications in general and in its own therapeutic
recommendations, as evidenced by inclusion of a health econo-
mist in the Task Force. Thus, the current recommendation for
the ﬁrst tsDMARD considers its entire net proﬁle (risk/beneﬁt/
costs); this aspect was also addressed for other therapies,
Box 1 Research agenda
1. After insufﬁcient response to MTX, is step-up therapy using a combination of csDMARDs as efﬁcacious as step-up therapy using a
bDMARD? Such trials should be thoroughly performed by deﬁning an appropriate end point, adhering to the a priori primary end
point, and recruiting/evaluating sufﬁcient numbers of patients in accordance with the original power calculation.
2. Can triple therapy with MTX, sulfasalazine and hydroxychloroquine be regarded as a treatment with ‘three different DMARDs’ or is
it just a ‘single DMARD strategy’?
3. What is the most successful tapering strategy of glucocorticoids after bridging or longer-term therapy?
4. What is the balance of beneﬁt/harm of long-term (>6 months) treatment with glucocorticoids at doses up to 10 mg/day in
established RA?
5. How long can low-dose glucocorticoids be applied with beneﬁt and without causing harm?
6. How do biological agents plus MTX compare with MTX plus low-dose glucocorticoids in patients with early RA?
7. Is induction therapy with bDMARDs plus MTX as a ﬁrst treatment strategy followed by withdrawal of the biological agent after 6–
12 months as promising an option for abatacept and tocilizumab as it appears to be for TNF inhibitors, and can therefore an
induction regimen with bDMARDs plus MTX become a new therapeutic paradigm?
8. With respect to the efﬁcacy and safety of tofacitinib, can biological agents be safely used after tofacitinib (with or without a
washout period) and can tofacitinib be safely and effectively used after abatacept, rituximab and tocilizumab?
9. How comparable are the different biological agents to each other and to tofacitinib?
10. Are there, aside from rituximab, differences in responsiveness to bDMARDs between seropositive and seronegative patients?
11. Is there a difference between reducing dose and increasing interval when tapering biological agents after the targeted state has
been reached?
12. Is it correct that, when patients have not reached the target on MTX, those with risk factors for bad outcome beneﬁt more from
the addition of a biological agent than from switching to or addition of csDMARDs?
13. Is it correct that, when patients have not reached the target on MTX, those with no risk of bad outcome beneﬁt equally from
switching to or addition of csDMARDs as they would from addition of a biological agent?
14. Can we ﬁnd common or speciﬁc predictors of response to the different biological agents, csDMARDs and tsDMARDs?
15. What are the risk factors that deﬁne patients who beneﬁt from a more intensive initial treatment modality?
16. Which factors predict who will be able to successfully withdraw bDMARDs and who not?
17. How big is the difference in clinical, functional and structural efﬁcacy when treatment strategies aiming to achieve remission are
compared with those aiming to achieve low disease activity?
18. How can immunogenicity of bDMARDs explain the similarity of clinical trial data observed with both immunogenic and
non-immunogenic compounds?
19. How good is patient adherence to biological agents and can lack of adherence be related to loss of efﬁcacy?
20. Is measurement of serum drug and/or drug antibody levels useful in clinical practice?
21. Which degree of improvement is needed at 3 months to ensure reaching the treatment target at 6 months and beyond?
22. How long should we aim to use concomitant GC therapy in RA?
23. To understand more in detail how the molecular mechanisms of genomic and non-genomic GC actions (and their dose
dependency!) mediate the clinically wanted beneﬁts but also the known adverse effects.
24. To improve treatment with conventional GCs (eg, in respect of timing and circadian rhythms) and develop innovative GC or novel
GC receptor ligands.
25. To evaluate further possibilities to reduce the (subjective) adverse events of MTX, the anchor drug in treating RA.
26. Long-term safety data in real life (registries) are needed for non-TNF inhibitor biological agents and tofacitinib.
27. Is tocilizumab monotherapy as efﬁcacious and safe as other bDMARDs plus MTX?
28. Can bDMARDs and/or sDMARDs be safely withdrawn in patients with established disease who have long-standing (>6 months)
remission according to the ACR–EULAR deﬁnition?
ACR, American College of Rheumatology; bDMARD, biological DMARD; csDMARD, conventional synthetic DMARD; DMARD,
disease-modifying antirheumatic drug; EULAR, European League against Rheumatism; GC, ; MTX, methotrexate; RA, rheumatoid
arthritis; TNF, tumour necrosis factor; tsDMARD, targeted synthetic DMARD.
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especially boDMARDs, in 2010.3 8 However, it is evident that
economic approaches will differ between countries depending
on their healthcare systems. This recommendation was voted on
while the Task Force had knowledge about the US label and lit-
erature on tofacitinib, but before the negative opinion of EMA
became known.
Finally, tapering bDMARDs was addressed, as new data had
become available (item 12) that suggest that, once low disease
activity and, especially, remission is sustained, a dose reduction
of bDMARDs will allow maintenance of the good outcome.
The Task Force did not address issues of immunogenicity
reported for some but not other bDMARDs, since the SLRs per-
formed did not reveal any signiﬁcant differences in efﬁcacy
among the different bDMARDs and also since agents that
induce drug antibodies were not shown to convey worse
outcome than agents that do not.171 In addition, although there
are data available that suggest that baseline TNF levels may
predict response to TNF inhibitor therapy,150 the Task Force did
not focus on predictors of response and regarded this aspect as
part of the research agenda.
Thus, looking at the major changes in comparison with the
2010 recommendations,3 this update placed combination
therapy of csDMARDs at the same level as MTX monotherapy
as a ﬁrst-line DMARD strategy (in addition to its potential use
as a second csDMARD strategy after insufﬁcient efﬁcacy of
MTX in patients without adverse prognostic markers), all pref-
erably in combination with glucocorticoids. For the use of bio-
logical agents as a second-line DMARD strategy in patients with
adverse prognostic signs, a preference for TNF inhibitors is no
longer maintained, and the use of bDMARDs in combination
with csDMARDs is generally advocated. Further, biosimilars
and tofacitinib are addressed. Compared with the 2012 update
of the ACR management recommendations,172 the EULAR
update is of a more general nature and avoids discussing individ-
ual case scenarios, focuses less on safety aspects (which are
covered in the respective SLR and are widely available in the
respective package inserts), addresses glucocorticoids, disregards
minocycline, does not advocate the use of biological agents as
monotherapy or part of the initial treatment strategy, places toci-
lizumab at the same level as other biological agents, and also
discusses tofacitinib and biosimilars.
One of the most important aspects in the context of develop-
ing recommendations or guidelines is their implementation173
and actual application. Implementation is a multistep procedure,
which beneﬁts from the adoption of international recommenda-
tions by local societies, as was the case for the 2010 EULAR
recommendations.9–12 Nevertheless, adoption of therapeutic
targets and means to reach these targets in clinical practice have
been shown to be far from ideal,174 and, in a very recent ana-
lysis of the implementation of guidelines and recommendations
across Europe, there was some room for further improve-
ment.175 Thus, it will clearly be a challenge for EULAR to
ensure and ﬁnd ways to monitor whether these updated recom-
mendations are at least considered widely in clinical care.
The 2013 update of the EULAR recommendations was devel-
oped by a Task Force consisting of 33 members from 11
European countries and the USA; among them were four
patients, an infectious disease specialist and a health economist.
While it may be seen to be a limitation that the rheumatologists
of the Task Force came only from Europe and none was from
the USA, Japan or other countries, it is important to state that
most of these recommendations are based on a large body of
evidence and only a few reﬂect elements of expert opinion (see
also table 2). Even if these recommendations are regarded to
reﬂect primarily a European view, they can be used as a template
for slightly amended versions by other national or international
rheumatological societies outside Europe, as has, indeed, been
the case with the 2010 recommendations.9 10 The recommenda-
tions are intended to assist and inform rheumatologists, patients,
hospital managers, representatives of social security agencies,
regulatory authorities and government ofﬁcials. Although some
of the medications discussed are not yet licensed at all or in all
countries, they are expected to receive this status in due course,
and sufﬁcient literature was available to address them accord-
ingly. Importantly, most of the recommendations have a very
high level of evidence, received a large majority vote, and have
a high strength of recommendation. Nevertheless, some items
were developed just by expert opinion or comprise a mixture of
high evidence level and expert opinion, and this drove the
research agenda presented in box 1. It is rewarding to see that
some of the items of the research agenda presented in 2010 (eg,
items 2, 4, 6)3 have already been partly or fully addressed and
this, indeed, informed the current update.
The 2013 update of the EULAR recommendations provides
the current state of thinking in the ﬁeld of RA management
from a mainly European perspective. The updated recommenda-
tions comprise the synthesis of available information based pri-
marily on efﬁcacy and safety of the agents addressed, with
inclusion of some health economic considerations. They should
enable optimal outcomes in our patients. However, a signiﬁcant
proportion of patients may still not reach the desired therapeutic
target. Therefore new therapies are still needed and, indeed, are
on the horizon. Also, some items will need to be further devel-
oped in the context of future research activities. Consequently,
we will carefully follow the developments in the ﬁeld and antici-
pate that yet another update may be needed in 2–3 years. Until
then, we hope that the current recommendations will ﬁnd their
way into clinical practice either directly or through national
societies that may wish to use them as a framework for develop-
ment of local guidance documents.
Author afﬁliations
1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna,
Vienna, Austria
22nd Department of Medicine, Hietzing Hospital Vienna, Vienna, Austria
3Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
4Atrium Medical Center, Heerlen, The Netherlands
5Department of Rheumatology, Leiden University Medical Center, Leiden, The
Netherlands
6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds,
Chapel Allerton Hospital, Leeds, UK
7NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals
NHS Trust, Leeds, UK
8Department of Rheumatology and Clinical Immunology, Charité-University Medicine,
Free University and Humboldt University, Berlin, Germany
9Clinical Immunology Free University and Humboldt University, Berlin, Germany
10Department of Rheumatology B, Cochin Hospital, René Descartes University, Paris,
France
11Department of Rheumatology, Nîmes University Hospital, Montpellier I University,
Nimes, France
12Rheumatology Department, Paris 06 UPMC University, AP-HP, Pite-Salpetriere
Hospital, Paris, France
13Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
14Hospital Garcia de Orta, Almada, Portugal
15Oregon Health and Science University, Portland, Oregon, USA
16EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE),
Zurich, Switzerland
17Department of Rheumatology and Clinical Immunology, University Medical Center
Utrecht, Utrecht, The Netherlands
18VU University Medical Center, Amsterdam, The Netherlands
19Service d’Immuno-Rhumatologie, Montpellier University, Lapeyronie Hospital,
Montpellier, France
20Academic Clinical Unit of Rheumatology, Department of Internal Medicine,
University of Genova, Genova, Italy
504 Smolen JS, et al. Ann Rheum Dis 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573
Recommendation
Protected by copyright.
 o
n
 N
ovem
ber 17, 2019 at Radboud University Nijmegen.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204573 on 25 O
ctober 2013. Downloaded from
 
212nd Hospital Department, Institute of Rheumatology, University of Belgrade
Medical School, Belgrade, Serbia
22Department of Rheumatology, Erasmus MC, University Medical Center,
Dr Molewaterplein, Rotterdam, The Netherlands
23Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
24Hopitaux Universitaires Paris Sud, AP-HP, and Université Paris-Sud, Le Kremlin
Bicetre, France
25Institute of Rheumatology and Clinic of Rheumatology, Charles University, Prague,
Czech Republic
26Department of Rheumatology, Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
27Department of Internal Medicine, University of Cologne, Cologne, Germany
28King’s College School of Medicine, Weston Education Centre, London, UK
29Jyväskylä Central Hospital, Jyväskylä, Finland
30Medcare Oy, Äänekoski, Finland
31Division of Clinical Decision Making, Informatics and Telemedicine, Tufts University
School of Medicine, Boston, Massachusetts, USA
Acknowledgements We would like to thank the European League Against
Rheumatism (EULAR) for providing the funds to perform this task.
Contributors JSS and RL wrote the ﬁrst draft with help from DvdH. SR, JN
and CGV performed the literature review. All authors participated in the
activities of the Task Force and have provided important contributions to the
manuscript.
Funding European League Against Rheumatism.
Competing interests All the participants in this initiative have disclosed any
conﬂicts of interest. After review by the EULAR Steering Committee, these potential
conﬂicts have been considered as either absent or acceptable with this initiative. The
individual declarations of conﬂicts are available on demand at the EULAR secretariat
and are summarised below as remuneration for consultation and/or speaking
engagements (‘R’), research funding (‘F’) or ‘none’. JSS—R: Abbott/Abbvie, Amgen,
Astra-Zeneca, BMS, Celgene, Glaxo, Inﬁnity, Janssen, Lilly, Medimmune, MSD,
Novo-Nordisk, Pﬁzer, Roche, Samsung, Sandoz, Sanoﬁ, UCB, Vertex; F: Abbott,
BMS, MSD, Pﬁzer, Roche, UCB. RL—R: Abbott/AbbVie, Ablynx, Amgen,
Astra-Zeneca, Bristol Myers Squibb, Centocor, Glaxo-Smith-Kline, Novartis, Merck,
Pﬁzer, Roche, Schering-Plough, UCB, Wyeth; F: Abbott, Amgen, Centocor, Novartis,
Pﬁzer, Rhoche, Schering-Plough, UCB, Wyeth. FCB—R: Abbvie, Merck. MB—R:
Abbott, Bristol Myers-Squibb, Chugai, Pﬁzer, Roche; F: Pﬁzer. GB—Abbott/Abbvie,
BMS, MSD, Pﬁzer, Roche, UCB; F: Abbott, BMS, Pﬁzer, Roche, UCB. MD—R:
Abbott/Abbvie, Pﬁzer, Roche, UCB, BMS, Hospira, Lilly, Novartis, Sanoﬁ; F: Abbott,
Roche. PE—R: MSD, Pﬁzer, Abbott, Novartis, UCB, Roche, BMS, Lilly, Takeda,
Janssen; F: MSD, Roche. CGV—R: Abbvie, BMS, MSD, Pﬁzer, Roche-Chugai, UCB;
F: Expanscience, Nordic Pharma, Pﬁzer. LG—R: Abbott, BMS, Chugai, Pﬁzer, Roche,
UCB. JN—R: UCB. SR—R: Fundação para a Ciência e Tecnologia. KW—R: Pﬁzer,
Genentech, UCB, Abbott. MdW—R: Abbvie. DA—R: Pﬁzer, Abbott, MSD, Janssen,
Grünenthal, Medac; F: MSD. NB—R: Pﬁzer, BMS, Roche. JWJB—R: Abbott, BMS,
MSD, Mundipharma, Novartis, Pﬁzer, Roche, UCB; F: Abbott, BMS, MSD, Novartis,
Pﬁzer, Roche, UCB. MB—R: Novartis, Celgene, BMS, UCB, AstraZeneca, Roche,
Mundipharma. FB—R: Abbott, Amgen, Horizon, Medac, Mundipharma, Pﬁzer,
Roche, Servier, UCB, Zalicos; F: Horizon, Medac, Pﬁzer. BC—BMS, Celgene, Lilly,
MERCK, Novartis, Pﬁzer, Roche-Chugai, UCB; F: Pﬁzer. MC—R: Abbott, Pﬁzer,
Sanoﬁ Aventis, Theva, Celgene, Mundipharm, BMS, Actelion; F: BMS, Actelion. ND
—R: Pﬁzer, MSD, Abbott, Roche. JMWH—none. MK—none. TKK—R: Abbott,
Astra-Zeneca, BMS, MSD, Pﬁzer, Roche, UCB; F: BMS, MSD, Pﬁzer, Roche, UCB.
XM—BMS, GSK, Neovacs, Pﬁzer, Roche, UCB. KP—R: AbbVie, Gedeon Richter,
Roche, Pﬁzer, MSD, Amgen, Servier, BMS. PLCMvR—R: Abbvie, BMS, Roche, Pﬁzer,
UCB, MSD; F: Abbvie, BMS, Roche, Pﬁzer, UCB. ARR—R: Abbott, BMS, UCB, MSD,
Roche, Chugai, Pﬁzer. MSV—none. DLS—R: MSD, UCB, BMS; F: Pﬁzer. TSI—R:
Abbott, Medac, Pﬁzer, UCB, BMS, GSK, MSD; F: Abbott, Pﬁzer. JBW—None. DvdH
—R: Abbott, Amgen, AstraZeneca, BMS, Centocor, Daiichi, Eli-Lilly, GSK, Janssen
Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pﬁzer, Roche, Sanoﬁ-Aventis,
UCB; Director of Imaging Rheumatology bv; F: UCB, Pﬁzer.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Smolen JS, Aletaha D, Koeller M, et al. New therapies for the treatment of
rheumatoid arthritis. Lancet 2007;370:1861–74.
2 Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature
of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73:3–5.
3 Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.
4 Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the
management of rheumatoid arthritis with synthetic disease-modifying
antirheumatic drugs: a systematic literature review informing the EULAR
recommendations for the management of rheumatoid arthritis. Ann Rheum Dis
2010;69:1004–9.
5 Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the
management of rheumatoid arthritis with biological disease-modifying
antirheumatic drugs: a systematic literature review informing the EULAR
recommendations for the management of RA. Ann Rheum Dis 2010;69:976–86.
6 Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of
rheumatoid arthritis with glucocorticoids: a systematic literature review informing
the EULAR recommendations for the management of rheumatoid arthritis. Ann
Rheum Dis 2010;69:1010–14.
7 Knevel R, Schoels M, Huizinga TW, et al. Current evidence for a strategic approach
to the management of rheumatoid arthritis with disease-modifying antirheumatic
drugs: a systematic literature review informing the EULAR recommendations for the
management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987–94.
8 Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in
rheumatoid arthritis: a systematic literature review informing the EULAR
recommendations for the management of rheumatoid arthritis. Ann Rheum Dis
2010;69:995–1003.
9 Mok CC, Tam LS, Chan TH, et al. Management of rheumatoid arthritis: consensus
recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol
2011;30:303–12.
10 El Zorkany B, Alwahshi HA, Hammoudeh M, et al. Suboptimal management of
rheumatoid arthritis in the Middle East and Africa: could the EULAR
recommendations be the start of a solution?. Clin Rheumatol 2013;32:151–9.
11 Wollenhaupt J, Albrecht K, Kruger K, et al. The new 2012 German
recommendations for treating rheumatoid arthritis : differences compared to the
European standpoint. Z Rheumatol 2013;72:6–9.
12 Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association
recommendations for pharmacological management of rheumatoid arthritis with
traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol
2012;39:1559–82.
13 Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efﬁcacy of conventional synthetic
disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib—a
systematic literature review informing the 2013 update of the EULAR
recommendations for management of rheumatoid arthritis. Ann Rheum Dis
2014;73:510–15.
14 Nam JL, Ramiros S, Gaujoux-Viala C, et al. 2013 update of the evidence for the
management of rheumatoid arthritis with biological disease-modifying
antirheumatic drugs: a systematic literature review informing the EULAR
recommendations for the management RA. Ann Rheum Dis 2013; submitted.
15 Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological
DMARDs—a systematic literature review informing the 2013 update of the EULAR
recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2013;
submitted.
16 OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-Based
Medicine. The Oxford 2011 Levels of Evidence, 2011. Ref Type: Grant
17 Widdiﬁeld J, Bernatsky S, Paterson JM, et al. Quality care in seniors with
new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res
(Hoboken) 2011;63:53–7.
18 Bonafede MM, Fox KM, Johnson BH, et al. Factors associated with the initiation
of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis:
a retrospective claims database study. Clin Ther 2012;34:457–67.
19 van Eijk-Hustings Y, van TA, Bostrom C, et al. EULAR recommendations for the
role of the nurse in the management of chronic inﬂammatory arthritis. Ann Rheum
Dis 2012;71:13–19.
20 Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based
recommendations for cardiovascular risk management in patients with rheumatoid
arthritis and other forms of inﬂammatory arthritis. Ann Rheum Dis
2010;69:325–31.
21 Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access
to treatment: health burden and costs. Eur J Health Econ 2008;8(Suppl 2):
S49–60.
22 Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291
diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the
Global Burden of Disease Study 2010. Lancet 2012;380:2197–223.
23 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160
sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the
Global Burden of Disease Study 2010. Lancet 2012;380:2163–96.
24 Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment:
outcome and cost-utility of treatments. Eur J Health Econ 2008;8(Suppl 2):S95–106.
Smolen JS, et al. Ann Rheum Dis 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573 505
Recommendation
Protected by copyright.
 o
n
 N
ovem
ber 17, 2019 at Radboud University Nijmegen.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204573 on 25 O
ctober 2013. Downloaded from
 
25 Kärrholm J, Garelick G, Herberts P. Swedish Hip reaplecement Register—Annual
Report 2006. 2008. http://www.jruorthopguse/ (accessed 23 Aug 2008).
26 Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of
biological treatment options after tumour necrosis factor alpha inhibitor failure in
rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann
Rheum Dis 2012.
27 Schiff M, Fleischmann R, Weinblatt M, et al. Abatacept sc versus adalimumab on
background methotrexate in RA: one year results from the AMPLE study. Ann
Rheum Dis 2012;71(Suppl 3):60. Ref Type: Abstract
28 GabayD C, Emery P, van Vollenhoven R, et al. Tocilizumab (TCZ) monotherapy is
superior to adalimumab (ADA) monotherapy in reducing disease activity in patients
with rheumatoid arthritis (ra): 24-week data from the phase 4 ADACTA trial. Ann
Rheum Dis 2012;71(Suppl 3):152. Ref Type: Abstract
29 van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of inﬂiximab
compared with addition of sulfasalazine and hydroxychloroquine to methotrexate
in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a
randomised trial. Lancet 2009;374:459–66.
30 van der KE, Klarenbeek NB, Guler-Yuksel M, et al. A decrease in disease activity
score (DAS) level is associated with a decrease in health assessment questionnaire
(HAQ) score, independent of follow-up duration, during 5 years of tightly
controlled treatment: results from the BeSt study. Ann Rheum Dis
2011;70:168–71.
31 Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the
treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322–8.
32 Radner H, Neogi T, Smolen JS, et al. Performance of the 2010 ACR/EULAR
classiﬁcation criteria for rheumatoid arthritis: a systematic literature review. Ann
Rheum Dis 2013.
33 Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target:
recommendations of an international task force. Ann Rheum Dis 2010;
69:631–7.
34 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European
League Against Rheumatism provisional deﬁnition of remission in rheumatoid
arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.
35 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and
radiographic consequences of achieving stable low disease activity and remission
with adalimumab plus methotrexate or methotrexate alone in early rheumatoid
arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann
Rheum Dis 2013;72:64–71.
36 Gabay C, Emery P, van VR, et al. Tocilizumab monotherapy versus adalimumab
monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised,
double-blind, controlled phase 4 trial. Lancet 2013;381:1541–50.
37 Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice.
Rheumatology 2007;46:975–9.
38 Klarenbeek NB, Koevoets R, Van der Heijde DM, et al. Association with joint
damage and physical functioning of nine composite indices and the 2011 ACR/
EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis
2011;70:1815–21.
39 Koevoets R, van der Heijde D. Being in remission or in low disease activity in
rheumatoid arthritis: different meaning with the use of different composite scores.
Arthritis Rheum 2009;60(Suppl):957.
40 Smolen JS, Han C, Van der Heijde DM, et al. Radiographic changes in rheumatoid
arthritis patients attaining different disease activity states with methotrexate
monotherapy and inﬂiximab plus methotrexate: the impacts of remission and
TNF-blockade. Ann Rheum Dis 2009;68:823–7.
41 Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission
according to the Disease Activity Score in 28 joints and is driven by residual
swollen joints. Arthritis Rheum 2011;63:3702–11.
42 Balsa A, de Miguel E, Castillo C, et al. Superiority of SDAI over DAS-28 in
assessment of remission in rheumatoid arthritis patients using power Doppler
ultrasonography as a gold standard. Rheumatology (Oxford) 2010;49:683–90.
43 Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid
arthritis, the new ACR/EULAR deﬁnition of remission identiﬁes patients with
persistent absence of functional disability and suppression of ultrasonographic
synovitis. Ann Rheum Dis 2013;72:245–9.
44 Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid
arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum 2013.
45 Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical
trials of patients with rheumatoid arthritis: EULAR/ACR collaborative
recommendations. Ann Rheum Dis 2008;67:1360–4.
46 Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical
function and quality of life in patients with rheumatoid arthritis. Rheumatology
(Oxford) 2011;50:381–8.
47 Kiely P, Walsh D, Williams R, et al. Outcome in rheumatoid arthritis patients with
continued conventional therapy for moderate disease activity—the early RA
network (ERAN). Rheumatology (Oxford) 2011;50:926–31.
48 Montag K, Gingold M, Boers A, et al. Disease-modifying anti-rheumatic drug
usage, prescribing patterns and disease activity in rheumatoid arthritis patients in
community-based practice. Intern Med J 2011;41:450–5.
49 Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of
treatment predicts response to therapy after one year in rheumatoid arthritis
patients. Arthritis Rheum 2007;56:3226–35.
50 Visser K, van der Heijde D. Optimal dosage and route of administration of
methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann
Rheum Dis 2009;68:1094–9.
51 Aletaha D, Martinez-Avila J, Kvien TK, et al. Deﬁnition of treatment response in
rheumatoid arthritis based on the simpliﬁed and the clinical disease activity index.
Ann Rheum Dis 2012;71:1190–6.
52 van Gestel AM, van Riel PLCM. Validation of rheumatoid arthritis improvement
criteria that include simpliﬁed joint counts. Arthritis Rheum 1998;41:1845–50.
53 Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the “anchor drug” for the treatment
of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(Suppl 31):S178–85.
54 Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity
states in clinical trials of rheumatoid arthritis. Arthritis Rheum 2008;58:2622–31.
55 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study—A
multicenter, randomized, double-blind clinical trial of combination therapy with
adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not had previous
methotrexate treatment. Arthritis Rheum 2006;54:26–37.
56 St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of inﬂiximab and
methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
Arthritis Rheum 2004;50:3432–43.
57 Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the
combination of etanercept and methotrexate compared with each treatment alone
in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Lancet 2004;363:675–81.
58 Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved
clinical outcomes with rituximab plus methotrexate in early active rheumatoid
arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39–46.
59 Westhovens R, Robles M, Ximenes AC, et al. Clinical efﬁcacy and safety of
abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor
prognostic factors. Ann Rheum Dis 2009;68:1870–7.
60 Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial
in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Ann Rheum Dis 2013. Published Online First: 28 May 2013. doi:10.1136/
annrheumdis-2013-203243
61 van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid
supplementation on the toxicity and efﬁcacy of methotrexate in rheumatoid
arthritis: a forty-eight week, multicenter, randomized, double-blind,
placebo-controlled study. Arthritis Rheum 2001;44:1515–24.
62 Salliot C, van der HD. Long-term safety of methotrexate monotherapy in patients
with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis
2009;68:1100–4.
63 Burmester G, Kivitz A, Kupper H, et al. Efﬁcacy, pharmacokinetics, and safety of
different doses of methotrexate in combination with adalimumab: results from the
CONCERTO trial. Ann Rheum Dis 2013;72(Suppl 3):72.
64 Katchamart W, Trudeau J, Phumethum V, et al. Efﬁcacy and toxicity of
methotrexate (MTX) monotherapy versus MTX combination therapy with
non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a
systematic review and meta-analysis. Ann Rheum Dis 2009;68:1105–12.
65 van der Heijde DM, van Riel PL, Nuver-Zwart , et al. Effects of hydroxychloroquine
and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet
1989;1:1036–8.
66 Smolen JS, Kalden JR, Scott DL, et al. Efﬁcacy and safety of leﬂunomide compared
with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind,
randomised, multicentre trial. Lancet 1999;353:259–66.
67 Sharp JT, Strand V, Leung H, et al. Treatment with leﬂunomide slows radiographic
progression of rheumatoid arthritis. results from three randomized controlled trials
of leﬂunomide in patients with active rheumatoid arthritis. Arthritis Rheum
2000;43:495–505.
68 Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with
leﬂunomide compared with placebo and methotrexate. Arch Int Med
1999;159:2542–50. Ref Type: Generic.
69 Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early
rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial
of sulphasalazine and methotrexate compared with the single components. Ann
Rheum Dis 1999;58:220–5.
70 Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in
combination with disease-modifying antirheumatic drugs for the treatment of
rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis
(ReAct) trial. Ann Rheum Dis 2007;66:732–9.
71 Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour
necrosis factor alpha inhibitors in combination with either methotrexate or
leﬂunomide. Ann Rheum Dis 2009;68:1856–62.
72 van Riel PL, van Gestel AM, van de Putte LB. Long-term usage and side-effect
proﬁle of sulphasalazine in rheumatoid arthritis. Br J Rheumatol 1995;
34(Suppl 2):40–2.
506 Smolen JS, et al. Ann Rheum Dis 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573
Recommendation
Protected by copyright.
 o
n
 N
ovem
ber 17, 2019 at Radboud University Nijmegen.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204573 on 25 O
ctober 2013. Downloaded from
 
73 Capell HA. Clinical efﬁcacy of sulphasalazine—a review. Br J Rheumatol 1995;34
(Suppl 2):35–9.
74 Pullar T, Hunter JA, Capell HA. Sulphasalazine in the treatment of rheumatoid
arthritis: relationship of dose and serum levels to efﬁcacy. Br J Rheumatol
1985;24:269–76.
75 Food and Drug Administration. Azulﬁdine EN-tabs. 2012. http://www.accessdata.
fda.gov/drugsatfda_docs/label/2012/007073s125lbl.pdf (accessed 7 Sep2013).
76 Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efﬁcacy of the
P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of
rheumatoid arthritis in patients with active disease despite treatment with
methotrexate or sulphasalazine. Ann Rheum Dis 2012;71:1630–5.
77 Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat
Rev Rheumatol 2009;5:382–90.
78 Pincus T, Ferraccioli G, Sokka T, et al. Evidence from clinical trials and long-term
observational studies that disease-modifying anti-rheumatic drugs slow
radiographic progression in rheumatoid arthritis: updating a 1983 review.
Rheumatology (Oxford) 2002;41:1346–56.
79 Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases:
re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol
2011;23:278–81.
80 Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk
of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011;17:115–20.
81 Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with
improvement in lipid proﬁles in rheumatoid arthritis patients. Arthritis Care Res
(Hoboken) 2011;63:530–4.
82 Scherbel AL, Schuchter SL, Harrison JW. Comparison of effects of two antimalarial
agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with
rheumatoid arthitis. Cleve Clin Q 1957;24:98–104.
83 Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the
management of rheumatoid arthritis with synthetic disease modifying antirheumatic
drugs: A systematic literature review informing the EULAR recommendations for the
management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004–9.
84 van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination
treatment versus biological treatment in methotrexate-refractory early rheumatoid
arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot
trial. Lancet 2012;379:1712–20.
85 de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination
of DMARDs is better than methotrexate monotherapy: ﬁrst results of the tREACH
trial. Ann Rheum Dis 2013;72:72–8.
86 Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness
study of oral triple therapy versus etanercept plus methotrexate in early aggressive
rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Arthritis Rheum 2012;64:2824–35.
87 Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Inﬂiximab for 6 months added
on combination therapy in early rheumatoid arthritis: 2-year results from an
investigator-initiated, randomised, double-blind, placebo-controlled study (the
NEO-RACo Study). Ann Rheum Dis 2013;72:851–7.
88 O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for Active Rheumatoid Arthritis
after Methotrexate Failure. N Engl J Med 2013;369:307–18.
89 Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four
dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid
arthritis patients in the BeSt study. Ann Rheum Dis 2011;70:1039–46.
90 De Jong PHPD, Hazes JM, Luime JJ, et al. Randomized comparison of triple DMARD
therapy with methotrexate mono-therapy. Ann Rheum Dis 2013;72(Suppl 3):113.
91 Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs,
glucocorticoids, and biologic agents on radiographic progression in rheumatoid
arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled
studies, including 112 comparisons. Arthritis Rheum 2010;62:2852–63.
92 Bakker MF, Jacobs JW, Welsing PM, et al. Low-Dose Prednisone Inclusion in a
Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A
Randomized Trial. Ann Intern Med 2012;156:329–39.
93 Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for
glucocorticoid dosages and glucocorticoid treatment regimens: current questions
and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718–22.
94 Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to
the initial disease-modifying antirheumatic drug in patients with early active
rheumatoid arthritis reduces joint destruction and increases the remission rate: a
two-year randomized trial. Arthritis Rheum 2005;52:3360–70.
95 Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in
patients with early rheumatoid arthritis: long-term structural beneﬁts of a brief
intervention. Arthritis Rheum 2002;46:347–56.
96 Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early
rheumatoid arthritis retards radiographic progression over two years: a multicenter,
double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371–80.
97 Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and
radiographic outcomes of four different treatment strategies in patients with early
rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis
Rheum 2005;52:3381–90.
98 Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid
arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study
Group. N Engl J Med 1995;333:142–6.
99 Bijlsma JW, Hoes JN, Van Everdingen AA, et al. Are glucocorticoids DMARDs?
Ann N Y Acad Sci 2006;1069:268–74.
100 da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid
treatment in rheumatoid arthritis: published evidence and prospective trial data.
Ann Rheum Dis 2006;65:285–93.
101 Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on
the management of systemic glucocorticoid therapy in rheumatic diseases. Ann
Rheum Dis 2007;66:1560–7.
102 Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of
rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford)
2009;48:1114–21.
103 Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model
for the prediction of rapid radiographic progression in patients with rheumatoid
arthritis receiving different dynamic treatment strategies: post hoc analyses from
the BeSt study. Ann Rheum Dis 2010;69:1333–7.
104 Moreland LW, O’Dell JR, Paulus HE, et al. Two-year radiographic results from the
TEAR trial. Arthritis Rheum 2010;62(Suppl):S568–9.
105 Morel J, Duzanski MO, Cantagrel A, et al. Prospective follow-up of tocilizumab
treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data
from the french registry regate (registry–roactemra). Ann Rheum Dis 2013;72
(Suppl 3):456.
106 Hishitani Y, Ogata A, Shima Y, et al. Retention of tocilizumab and anti-tumour
necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol
2013;42:253–9.
107 Horak P, Skacelova M, Hejduk K, et al. Abatacept and its use in the treatment of
rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clin
Rheumatol 2013;32:1451–8.
108 Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in
patients with rheumatoid arthritis treated with rituximab in the autoimmunity and
rituximab registry. Arthritis Rheum 2010;62:2625–32.
109 Godot S, Gottenberg JE, Paternotte S, et al. Safety of surgery after rituximab
therapy in 133 patients with rheumatoid arthritis: Data from the AutoImmunity
and Rituximab registry. Arthritis Care Res (Hoboken) 2013. doi:10.1002/
acr.22056. [Epub ahead of print 10 Jun 2013].
110 Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of
subcutaneous abatacept versus adalimumab for rheumatoid arthritis: ﬁndings of a
phase IIIb, multinational, prospective, randomized study. Arthritis Rheum
2013;65:28–38.
111 Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved
clinical outcomes with rituximab plus methotrexate in early active rheumatoid
arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39–46.
112 Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efﬁcacy and safety of
rituximab in patients with active rheumatoid arthritis despite methotrexate
treatment: results of a phase IIB randomized, double-blind, placebo-controlled,
dose-ranging trial. Arthritis Rheum 2006;54:1390–400.
113 Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the
use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis
2011;70:909–20.
114 Strangfeld A, Pattloch D, Herzer P, et al. Risk of cancer recurrence or new tumors
in RA patients with prior malignancies treated with various biologic agents.
Arhritis Rheum 2013; (ACR 2013 Abstract online (https://ww2.rheumatology.org/
apps/MyAnnualMeeting/Abstract/36584).
115 Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group
study to demonstrate equivalence in efﬁcacy and safety of CT-P13 compared with
innovator inﬂiximab when coadministered with methotrexate in patients with
active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis
2013;72:1613–20.
116 Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre,
parallel-group, prospective study comparing the pharmacokinetics, safety, and
efﬁcacy of CT-P13 and innovator inﬂiximab in patients with ankylosing spondylitis:
the PLANETAS study. Ann Rheum Dis 2013;72:1605–12.
117 Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces
immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose
dependent manner. Ann Rheum Dis 2012;71:1914–5.
118 Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus
methotrexate monotherapy in patients with moderate to severe rheumatoid
arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88–96.
119 Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled
monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence
of clinical and radiographic beneﬁt from an x ray reader-blinded randomised
controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162–7.
120 Burmester GR, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in
combination and monotherapy versus methotrexate (MTX) in MTX-naive patients
(pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from
a randomised, placebo-controlled trial. Ann Rheum Dis 2013;72(Suppl):OP041.
Smolen JS, et al. Ann Rheum Dis 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573 507
Recommendation
Protected by copyright.
 o
n
 N
ovem
ber 17, 2019 at Radboud University Nijmegen.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204573 on 25 O
ctober 2013. Downloaded from
 
121 Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of
rheumatoid arthritis: efﬁcacy and feasibility. Ann Rheum Dis 2007;66(Suppl 3):iii56–60.
122 Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to
tocilizumab monotherapy in methotrexate inadequate responders: 24-week
symptomatic and structural results of a 2-year randomised controlled strategy trial
in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43–50.
123 Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate
provides better disease control in very early (<=4 months) versus early rheumatoid
arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann
Rheum Dis 2012;71:989–92.
124 van Riel PL, Taggart AJ, Sany J, et al. Efﬁcacy and safety of combination
etanercept and methotrexate versus etanercept alone in patients with rheumatoid
arthritis with an inadequate response to methotrexate: the ADORE study. Ann
Rheum Dis 2006;65:1478–83.
125 Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial
methotrexate monotherapy vs its combination with adalimumab) in management
of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology
(Oxford) 2009;48:1429–34.
126 Fleischmann R, van Vollenhoven RF, Smolen JS, et al. Long-Term Outcomes of
Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate
Compared with Methotrexate Alone Following a Targeted Treatment Approach.
Arthritis Rheum 2012;64(Suppl):S335–6.
127 Smolen JS, Fleischmann RM, Emery P, et al. Treating Rheumatoid Arthritis to
Target: Outcomes and Predictors in Early Rheumatoid Arthritis Patients Treated
with Adalimumab Plus Methotrexate, Methotrexate Alone, or Methotrexate Plus
Subsequent Adalimumab. Arthritis Rheum 2011;63(Suppl):S665. Ref Type:
Abstract.
128 Kavanaugh A, Emery P, Felischmann RM, et al. Withrawal of adalimumab in early
rheumatoid arthritis patients who attained stable low disease activity with
adalimumab plus methotrexate: esults of a phase 4, double-blind,
placebo-controlled trial. Rheumatology (Oxford) 2012;51(Suppl 3):iii27.
129 Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus
methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48
versus methotrexate therapy alone for DMARD-naive patients with early
rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis
2013;72:844–50.
130 Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission
with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo
in patients with early rheumatoid arthritis who achieved remission with etanercept
and methotrextate: the PRIZE study. Ann Rheum Dis 2013;72(Suppl 3):399.
131 Huizinga T, Kivitz AJ, Rell-Bakalarska M, et al. Sarilumab for the treatment of
moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized,
double-blind, placebo-controlled, international study. Ann Rheum Dis 2012;71
(Suppl 3):60. Ref Type: Abstract.
132 Hsu B, Sheng S, Smolen J, et al. Results from a 2-part, proof-of-concept,
dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of
sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid
arthritis patients despite methotrexate therapy. Arthritis Rheum 2011;63(Suppl):
S1034. Ref Type: Journal (Full).
133 Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised,
placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis
with an inadequate response to methotrexate. Ann Rheum Dis 2012;71:1183–9.
134 van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab
versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508–19.
135 Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in
combination with methotrexate in patients with active rheumatoid arthritis with an
inadequate response to tumour necrosis factor inhibitors: a randomised phase 3
trial. Lancet 2013;381:451–60.
136 Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib
monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495–507.
137 van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in
patients with rheumatoid arthritis on methotrexate: 12-Month data from a
24-month Phase 3 randomized radiographic study. Arthritis Rheum
2013;65:559–70.
138 Lee EB, Fleischmann RM, Hall S, et al. Radiographic, Clinical and Functional
Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Nave
Patients with Rheumatoid Arthritis. Arthritis Rheum 2012;64(Suppl):S1049.
139 Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of
anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA
2013;309:887–95.
140 Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources
use into grading recommendations. BMJ 2008;336:1170–3.
141 Garber K. Pﬁzer’s ﬁrst-in-class JAK inhibitor pricey for rheumatoid arthritis market.
Nat Biotechnol 2013;31:3–4.
142 Xeljanz Filmtbl 5mg (iH 08/13). 2013. http://www.kompendium.ch/prod/pnr/
1234138/de.
143 European Medicines Agency-CHMP. Summary of Opinion (Inﬂiximab biosimilar).
2013. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_
opinion_-_Initial_authorisation/human/002576/WC500144832.pdf,editors. Ref
Type: Online Source.
144 European Medicines Agency. European Medicines Agency recommends approval of ﬁrst
two monoclonal antibody biosimilars. 2013. http://www.ema.europa.eu/docs/en_GB/
document_library/Press_release/2013/06/WC500144941.pdf. Ref Type: Online Source.
145 European Medical Agency. Xeljanz. 2013. http://www.ema.europa.eu/ema/
indexjsp?curl=pages/medicines/human/medicines/002542/smops/Negative/human_
smop_000501jsp&mid=WC0b01ac058001d127 (accessed 25 May, 2014).
146 Committee for Medicinal Products for Human Use (CHMP). Meeting highlights
from the Committee for Medicinal Products for Human Use (CHMP). 22–25 July
2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/
news/2013/07/news_detail_001851.jsp&mid=WC0b01ac058004d5c1.
147 Pﬁzer. Pﬁzer Receives CHMP Negative Opinion Regarding Marketing Authorization
In Europe For Rheumatoid Arthritis Treatment XELJANZ (tofacitinib citrate). 2013.
http://press.pﬁzer.com/press-release/pﬁzer-receives-chmp-negative-opinion-
regarding-marketing-authorization-europe-rheumat (accessed 25 May 2013).
148 Tanaka Y, Hirata S, Saleem B, et al. Discontinuation of biologics in patients with
rheumatoid arthritis. Clin Exp Rheumatol 2013; (in press).
149 Kavanaugh A, Smolen JS. The when and how of biologics withdrawal in
rheumatoid arthritis—learning from large randomized controlled trials. Clin Exp
Rheumatol 2013;(in press).
150 Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of inﬂiximab after attaining
low disease activity in patients with rheumatoid arthritis: RRR (remission induction
by Remicade in RA) study. Ann Rheum Dis 2010;69:1286–91.
151 Chatzidionysiou K, Turesson C, Teleman A, et al. A Multicenter, Randomized,
Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of
Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission. Arthritis
Rheum 2012;64(Suppl):S336.
152 Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of
etanercept after treatment with etanercept and methotrexate in patients with
moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet
2013;381:918–29.
153 Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment
in patients with rheumatoid arthritis in sustained clinical remission: exploratory
analyses from the BeSt study. Ann Rheum Dis 2011;70:315–9.
154 Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid
arthritis on the basis of achievement of stable low disease activity with
adalimumab plus methotrexate or methotreate alone: the randomised controlled
OPTIMA trial. Lancet 2013; (in press).
155 Fautrel B, Gandjbakhch F, Foltz V, et al. Targeting the lowest efﬁcacious dose for
rheumatoid arthritis patients in remission: clinical and structural impact of a
stepdown strategy trial based on progressive spacing of TNF-blocker injections
(STRASS trial). Ann Rheum Dis 2013;72(Suppl 3):72.
156 Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologic-free remission study in
established rheumatoid arthritis—ORION study. Ann Rheum Dis 2013;72 (Supple
3):613.
157 Nampei A, Nagayama Y. Discontinuation of tocilizumab after attaining remission in
patients with rheumatoid arthritis. Ann Rheum Dis 2013;72(Suppl 3):877.
158 Batticciotto A, Varisco V, Antivalle M, et al. Dose reduction in patients with
rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum
Dis 2013;72(Suppl):877.
159 Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist
therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine
2009;76:350–5.
160 ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study
of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;
347:347–52.
161 O’Mahony R, Richards A, Deighton C, et al. Withdrawal of DMARDs in patients
with Rheumatoid Arthritis: a systematic review and meta-analysis. Ann Rheum Dis
2010;69:1823–6.
162 van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in
rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of
two cohort studies. Rheumatology (Oxford) 2012;51:1120–8.
163 Gonzalez A, Maradit KH, Crowson CS, et al. Do cardiovascular risk factors confer
the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in
non-rheumatoid arthritis patients? Ann Rheum Dis 2008;67:64–9.
164 Baecklund E, Iliadou A, Askling J, et al. Association of chronic inﬂammation, not
its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis
Rheum 2006;54:692–701.
165 Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients
with rheumatoid arthritis: a prospective study. Lancet 2002;
359:1173–7.
166 Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on
cardiovascular disease in patients with rheumatoid arthritis: a systematic literature
review. Rheumatology (Oxford) 2010;49:295–307.
167 Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and
the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic
literature review. Rheumatology (Oxford) 2011;50:518–31.
508 Smolen JS, et al. Ann Rheum Dis 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573
Recommendation
Protected by copyright.
 o
n
 N
ovem
ber 17, 2019 at Radboud University Nijmegen.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204573 on 25 O
ctober 2013. Downloaded from
 
168 Aletaha D, Funovits J, Breedveld FC, et al. Rheumatoid arthritis joint progression in
sustained remission is determined by disease activity levels preceding the period of
radiographic assessment. Arthritis Rheum 2009;60:1242–9.
169 Roux CH, Breuil V, Valerio L, et al. Etanercept compared to intraarticular
corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot
study. J Rheumatol 2011;38:1009–11.
170 Dernis E, Ruyssen-Witrand A, Mouterde G, et al. Use of glucocorticoids in
rheumatoid arthritis—pratical modalities of glucocorticoid therapy:
recommendations for clinical practice based on data from the literature and expert
opinion. Joint Bone Spine 2010;77:451–7.
171 Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term
clinical outcome with etanercept treatment and adalimumab treatment of
rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum
2012;64:3850–5.
172 Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of
Rheumatology recommendations for the use of disease-modifying antirheumatic
drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care
Res (Hoboken) 2012;64:625–39.
173 Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating
procedures for the elaboration, evaluation, dissemination, and implementation of
recommendations endorsed by the EULAR standing committees. Ann Rheum Dis
2004;63:1172–6.
174 Schoels M, Aletaha D, Smolen JS, et al. Follow-up standards and treatment targets
in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum
Dis 2010;69:575–8.
175 Stoffer MA, Smolen JS, Woolf A, et al. Development of patient-centred standards
of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis.
Published Online First: 6 Aug 2013. doi:10.1136/annrheumdis-2013-203743
Smolen JS, et al. Ann Rheum Dis 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573 509
Recommendation
Protected by copyright.
 o
n
 N
ovem
ber 17, 2019 at Radboud University Nijmegen.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204573 on 25 O
ctober 2013. Downloaded from
 
